講座　精神疾患の臨床　2　統合失調症

出版社： 中山書店
著者：
発行日： 2020-07-01
分野： 臨床医学：内科  >  精神医学
ISBN： 9784521748221
電子書籍版： 2020-07-01 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

16,500 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

16,500 円(税込)

購入する

商品紹介

統合失調症の病因・病態，治療，支援などについて，現在までの到達点（わかっていること），解明すべき点（わかっていないこと），課題などの最新情報を盛り込み，最新の国際疾病分類ICD-11に準拠して，解説．精神科医のスペシャリストはもちろん，当事者，当事者を取り囲む支援者たちが，明日からの診療や研究，支援をよりよいものにしていくことを目指して執筆している．

目次

  • 1章　当事者・家族に学ぶ 統合失調症の理解と支援
    2章　専門職に学ぶ統合失調症の理解と支援
    3章　ライフステージに沿った統合失調症の理解と支援
    4章　共に創る統合失調症の理解と支援に向けた対話
    5章　Topics－変革に向けて

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

はじめに

P.6 掲載の参考文献
1) Kasai K. Toward an interdisciplinary science of adolescence : Insights from schizophrenia research. Neurosci Res 2013 ; 75 : 89-93.
PubMed
2) 長谷川寿一 (監修), 笠井清登ほか (編). 思春期学. 東京大学出版会 ; 2015.
 
3) 東京ティーンコホートウェブサイト. http://ttcp.umin.jp
 
4) Okano H, et al. Brain/MINDS : A Japanese national brain project for marmoset neuroscience. Neuron 2016 ; 92 : 582-590.
PubMed
5) 村井俊哉. 統合失調症. 岩波書店 ; 2019.
 
6) Millan MJ, et al. Altering the course of schizophrenia : Progress and perspectives. Nat Rev Drug Discov 2016 ; 15 : 485-515.
PubMed
7) HeAL (Healthy Active Lives) 宣言 日本版. https://kokoro-zukan.com/archives/101#content
 
8) 熊谷晋一郎 (編). みんなの当事者研究 (臨床心理学 増刊第9号). 金剛出版 ; 2017.
 

1章 当事者・家族に学ぶ統合失調症の理解と支援

P.19 掲載の参考文献
1) Ragins M. A Road to Recovery. Mental Health America of Los Angeles ; 2002/前田ケイ (監訳). ビレッジから学ぶリカバリーへの道-精神の病から立ち直ることを支援する. 金剛出版 ; 2005.
 
2) 蔭山正子 (編著). 精神障がい者の家族への暴力というSOS-家族・支援者のためのガイドブック. 明石書店 ; 2016.
 
3) YPS横浜ピアスタッフ協会, 蔭山正子 (編著). 当事者が語る精神障がいとリカバリー-続・精神障がい者の家族への暴力というSOS. 明石書店 ; 2018.
 
4) 伊藤順一郎ほか (編). じょうずな対処今日から明日へ-学びあい支えあいリカバリー, 全改訂第1版. 認定NPO法人地域精神保健福祉機構・コンボ ; 2018.
 
P.24 掲載の参考文献
1) Mead S, et al. Peer support : A theoretical perspective. Psychiatr Rehabil J 2001 ; 25 (2) : 134-141.
PubMed
2) 相川章子. 精神障がいピアサポーター-活動の実践と効果的な養成・育成プログラム. 中央法規出版 ; 2013.
 
3) Repper J, et al. Peer Support Workers : Theory and Practice. Centre for Mental Health and Mental Health Network, NHS Confederation 2013. https://imroc.org/resources/5-peer-support-workers-theory-practice/
 
4) Repper J, et al. Peer Support Workers : A practical guide to implementation. Centre for Mental Health and Mental Health Network, NHS Confederation 2013. https://imroc.org/resources/5-peer-support-workers-practical-guide-implementation/
 
5) 宮本有紀, 佐々木理恵. ピアサポートスタッフが組織にもたらす効果. 日精協誌 2017 ; 36 (10) : 996-1002.
 
岩崎香. 障害ピアサポート-多様な障害領域の歴史と今後の展望. 中央法規出版 ; 2018.
 
P.31 掲載の参考文献
1) 科学技術・イノベーション動向報告 米国編. 独立行政法人 科学技術振興機構 研究開発戦略センター. 2008.
 
2) 2014 Research! America Advocacy Awards. https://www.researchamerica.org/news-events/events/research-partners-forums/2014-researchamericaadvocacy-awards
 
3) Illumina sequences DNA of American actress Glenn Close. News Medical. https://www.news-medical.net/news/20100311/Illumina-sequences-DNA-of-American-actress-Glenn-Close.aspx
 
4) Post by Former NIMH Director Thomas Insel : Celebrating Science. https://www.nimh.nih.gov/about/directors/thomas-insel/blog/2014/celebrating-science.shtml
 
5) 発刊の辞. 変態心理 1917 ; 1 (1) : 1-2.
 
6) 安藤俊太郎. 疫学. 日本統合失調症学会 (監修), 福田正人ほか (編), 統合失調症. 医学書院 ; 2013, pp115-127.
 
7) Hill AB. The Environment and Disease : Association or Causation? Proc R Soc Med 1965 ; 58 (5) : 295-300.
 
8) Bhattacharyya MK, et al. The wrinkled-seed character of pea described by Mendel is caused by a transposon-like insertion in a gene encoding starch-branching enzyme. Cell 1990 ; 60 : 115-122.
 
9) Bodkin JA, et al. Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene. Biol Psychiatry 2019 ; 86 : 523-535.
PubMed
北中淳子. うつの医療人類学. 日本評論社 ; 2014.
 
佐々木閑. 科学するブッダ-犀の角たち. 角川学芸出版 ; 2013.
 
兵頭晶子. 精神病の日本近代-憑く心身から病む心身へ (越境する近代). 青弓社 ; 2008.
 
P.41 掲載の参考文献
1) 夏苅郁子. 「人が回復する」ということについて-著者と中村ユキさんのレジリエンスの獲得を通しての検討. 精神経誌 2011 ; 113 (9) : 845-852.
 
2) 夏苅郁子. 人は, 人を浴びて人になる-心の病にかかった精神科医の人生をつないでくれた12の出会い. ライフサイエンス出版 ; 2017.
 
3) 夏苅郁子ほか. 「精神科担当医の診察態度」を当事者・家族はどのように評価しているか-約6,000人の調査結果とそれに基づく提言. 精神経誌 2018 ; 120 (10) : 868-886.
 
4) 夏苅郁子. 精神科医の診察能力・態度・コミュニケーション能力についてのアンケート. natsukari.jp/result/ (2020.3.18参照)
 
5) 西田淳志. 早期支援・家族支援のニーズ調査, 思春期精神病理の疫学と精神疾患の早期介入方策に関する研究. 平成21年度厚生労働科学研究こころの健康科学研究事業 (岡崎班) 総括・分担報告書. pp29-41.
 
6) NPO法人じんかれん. 2013～2015年 (平成25～27年) 家族会員を対象にしたアンケート調査. http://jinkaren.net/wp-content/uploads/2017/09/survey-2013-2015.pdf
 
7) 福田正人. 安心・信頼・希望と「ジブンのトリセツ」. こころの科学 2014 ; 177.
 
8) 岡田久美子. 統合失調症になってもだいじょうぶな社会を願って. 日本統合失調症学会 (監修), 福田正人ほか (編), 統合失調症. 医学書院 ; 2013, pp13-16.
 
9) 福田正人. 精神科医の「特権」に気づき役立てる. 精神経誌 2015 ; 117 (5) : 353-361.
 
10) 池淵恵美. Personal Support Specialistとしての精神科医. 精神経誌 2016 ; 118 : 242-248.
 
11) 笠井清登. 若手精神科医に求められる3つの基本 : 脳・生活・人生-価値精神医学に向けた理念共有. 精神経誌 2015 ; 117 (8) : 636-645.
 

2章 専門職に学ぶ統合失調症の理解と支援

P.49 掲載の参考文献
1) Salomon JA, et al. Common values in assessing health outcomes from disease and injury : Disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012 ; 380 (9859) : 2129-2143.
PubMed
2) Firth J, et al. The Lancet Psychiatry Commission : A blueprint for protecting physical health in people with mental illness. Lancet Psychiatry 2019 ; 6 (8) : 675-712.
PubMed
3) Kondo S, et al. Premature deaths among individuals with severe mental illness after discharge from longterm hospitalisation in Japan : A naturalistic observation during a 24-year period. BJPsych Open 2017 ; 3 (4) : 193-195.
 
4) Huhn M, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia : A systematic review and network meta-analysis. Lancet 2019 ; 394 (10202) : 939-951.
PubMed
5) Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP) : Description of lifestyle intervention. Diabetes Care 2002 ; 25 (12) : 2165-2171.
 
6) World Health Organization. Management of Physical Health Conditions in Adults with Severe Mental Disorders, 2018.
 
7) Choi J, Medalia A. Intrinsic motivation and learning in a schizophrenia spectrum sample. Schizophr Res 2010 ; 118 (1-3) : 12-19.
 
8) Burns T, Cohen A. Item-of-service payments for general practitioner care of severely mentally ill persons : Does the money matter? Br J Gen Pract 1998 ; 48 (432) : 1415-1416.
PubMed
9) Tuesley KM, et al. Colorectal, cervical and prostate cancer screening in Australians with severe mental illness : Retrospective nation-wide cohort study. Aust N Z J Psychiatry 2019 ; 53 (6) : 550-558.
PubMed
10) Kisely S, et al. Why do psychiatric patients have higher cancer mortality rates when cancer incidence is the same or lower? Aust N Z J Psychiatry 2016 ; 50 (3) : 254-263.
PubMed
11) Ayerbe L, et al. Disparities in the management of cardiovascular risk factors in patients with psychiatric disorders : A systematic review and meta-analysis. Psychol Med 2018 ; 48 (16) : 2693-2701.
PubMed
12) Viron MJ, Stern TA. The Impact of Serious Mental Illness on Health and Healthcare. Psychosomatics 2010 ; 51 (6) : 458-465.
PubMed
13) Gorczynski P, et al. Are people with schizophrenia adherent to diabetes medication? A comparative meta-analysis. Psychiatry Res 2017 ; 250 : 17-24.
PubMed
14) Peterson K, et al. Evidence Brief : Use of Patient Reported Outcome Measures for Measurement Based Care in Mental Health Shared Decision-Making. Washington (DC) : Department of Veterans Affairs (US) ; 2018.
 
15) Murray CJL. Global burden of disease. Le poids de la morbidite dans le monde. Quantifying the burden of disease : The technical basis for disability-adjusted life years. Bull World Heal Organ 1994 ; 72 (3) : 429-445.
 
16) World Health Organization. The global burden of disease : 2004 update. 2004.
 
17) Kyu HH, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017 : A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018 ; 392 (10159) : 1859-1922.
PubMed
18) Murray CJ, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010 : A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012 ; 380 (9859) : 2197-2223.
PubMed
19) GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017 : A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018 ; 392 (10159) : 1789-1858.
PubMed
20) 細田満和子. 障害調整生存年数 (DALY) についての概要と批判. 障害保健福祉研究情報システム. http://www.dinf.ne.jp/doc/japanese/prdl/jsrd/norma/n327/n327013.html
 
21) 社会・援護局障害保健福祉部企画課. 「国際生活機能分類-国際障害分類改訂版-」 (日本語版) の厚生労働省ホームページ掲載について. 平成14年8月5日. https://www.mhlw.go.jp/houdou/2002/08/h0805-1.html
 
22) World Health Organization. International Classification of Functioning, Disability and Health (ICF) framework to facilitate Interprofessional education and collaborative practice. https://www.who.int/hrh/news/2014/hrh_icf_framework/en/
 
23) Sado M, et al. The cost of schizophrenia in Japan. Neuropsychiatr Dis Treat 2013 ; 9 : 787.
PubMed
24) Wu EQ, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005 ; 66 (9) : 1122-1129.
PubMed
25) Frey S. The economic burden of schizophrenia in Germany : A population-based retrospective cohort study using genetic matching. Eur Psychiatry 2014 ; 29 (8) : 479-489.
 
26) Hastrup LH, et al. Societal Costs of Schizophrenia in Denmark : A Nationwide Matched Controlled Study of Patients and Spouses Before and After Initial Diagnosis. Schizophr Bull 2020 ; 46 (1) : 68-77.
 
27) Ranning A, et al. Morbidity and Mortality in the Children and Young Adult Offspring of Parents With Schizophrenia or Affective Disorders-A Nationwide Register-Based Cohort Study in 2 Million Individuals. Schizophr Bull 2020 ; 46 (1) : 130-139.
PubMed
28) Moran P, et al. Gene × Environment Interactions in Schizophrenia : Evidence from Genetic Mouse Models. Neural Plast 2016 ; 2016 : 2173748.
 
29) Akdeniz C, et al. The neurobiology of social environmental risk for schizophrenia : An evolving research field. Soc Psychiatry Psychiatr Epidemiol 2014 ; 49 (4) : 507-517.
PubMed
30) Tandon R, et al. Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophr Res 2008 ; 102 (1-3) : 1-18.
 
31) Lederbogen F, et al. City living and urban upbringing affect neural social stress processing in humans. Nature 2011 ; 474 (7352) : 498-501.
 
32) Attademo L, et al. Environmental pollution and risk of psychotic disorders : A review of the science to date. Schizophr Res 2017 ; 181 : 55-59.
PubMed
33) Hatzenbuehler ML. Structural stigma and health inequalities : Research evidence and implications for psychological science. Am Psychol 2016 ; 71 (8) : 742-751.
 
34) Corrigan PW, Kosyluk KA. Mental Illness Stigma : Types, Constructs, and Vehicles for Change. In : Corrigan P, ed. The Stigma of Diseases and Disability : Understanding Causes and Overcoming Injustices. Washington : American Psychological Association ; 2014, pp35-56.
 
35) Koike S, et al. Mental-health-related stigma among Japanese children and their parents and impact of renaming of schizophrenia. Psychiatry Clin Neurosci 2017 ; 71 (3) : 170-179.
PubMed
36) Schnyder N, et al. Association between mental health-related stigma and active help-seeking : Systematic review and meta-analysis. Br J Psychiatry 2017 ; 210 (4) : 261-268.
PubMed
37) 福田正人ほか. 統合失調症. 山脇成人ほか (編), 情動学シリーズ 2. 情動の仕組みとその異常. 朝倉書店 ; 2015, pp114-128.
 
38) Bush M (ed). Addressing Adversity : Prioritising adversity and trauma-informed care for children and young people in England. London : Young Minds Trust ; 2018. https://youngminds.org.uk/media/2142/ym-addressing-adversity-book-web.pdf
 
39) Radua J, et al. What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry 2018 ; 17 (1) : 49-66.
PubMed
P.59 掲載の参考文献
1) Bleuler E. Die Prognose der Dementia Praecox (Schizophrenie-Gruppe). Allg Z f Psychiat Psychisch-Gerichitliche Medizin 1908 ; 65 : 436-464.
 
2) Schneider K. Klinische Psychopathologie. Thieme ; 2007/針間博彦 (訳). 新版 臨床精神病理学. 文光堂 ; 2007.
 
3) Cooper JE, et al. Cross-national study of diagnosis of the mental disorders : Some results from the first comparative investigation. Am J Psychiatry 1969 ; 125 (10S) : 21-29.
 
4) Kendell RE, et al. Diagnostic criteria of American and British psychiatrists. Arc Gen Psychiatry 1971 ; 25 : 123-130.
 
5) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition. 1980/高橋三郎ほか (訳). DSM-III 精神障害の分類と診断の手引き. 医学書院 ; 1982.
 
6) Stephan H, et al. Structure of the psychotic disorders classification in DSM-5. Schizophr Res 2013 ; 150 (1) : 11-14.
 
7) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. 2013/日本精神神経学会 (日本語版用語監修), 高橋三郎ほか (監訳). DSM-5 精神疾患の診断・統計マニュアル. 医学書院 ; 2014.
 
8) World Health Organization. ICD-11 for Mortality and Morbidity Statistics. https://icd.who.int/browse11/l-m/en (2020.3参照)
 
9) Global Clinical Practice Networkホームページ. https://gcp.network/ja/ (2020.5参照)
 
10) Gaebel W. Status of psychotic disorders in ICD-11. Schizophr Bull 2012 ; 38 (5) : 895-898.
PubMed
11) World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders : Clinical descriptions and diagnostic guidelines. 1992/融道男ほか (監訳). ICD-10 精神および行動の障害-臨床記述と診断ガイドライン. 医学書院 ; 1993.
 
12) Zachar P. A Metaphysics of Psychopathology. The MIT Press ; 2014/植野仙経ほか (訳). 精神病理の形而上学. 学樹書院 ; 2018, pp158-160.
 
13) Andreasen NS. DSM and the death of phenomenology in America : An example of unintended consequences. Schizophr Bull 2007 ; 33 (1) : 108-112.
 
日本統合失調症学会 (監修), 福田正人ほか (編). 統合失調症. 医学書院 ; 2013.
 
Hoenig J. The Concept of Schizophrenia. Kraepelin-Bleuler-Schneider. Br J Psychiatry 1983 ; 142 : 547-556.
 
Kendler K. Phenomenology of Schizophrenia and the Representativeness of Modern Diagnostic Criteria. JAMA Psychiatry 2016 ; 173 : 1082-1092.
 
Insel T, et al. Research domain criteria (RDoC) : Toward a new classification framework for research on mental disorders. Am J Psychiatry 2010 ; 167 : 748-751.
 
P.69 掲載の参考文献
1) Green MF, et al. Neurocognitive deficits and functional outcome in schizophrenia : Are we measuring the "right stuff"? Schizophr Bull 2000 ; 26 : 119-136.
PubMed
2) Reichenberg A, Harvey PD. Neuropsychological impairments in schizophrenia : Integration of performance-based and brain imaging findings. Psychol Bull 2007 ; 133 : 833-858.
PubMed
3) 住吉チカ. 統合失調症と注意機能. 精神科 2014 ; 24 : 161-167.
 
4) Keefe RS, et al. The Brief Assessment of Cognition in Schizophrenia : Reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004 ; 68 : 283-297.
PubMed
5) Nuechterlein KH, Green MF. MATRICS Consensus Cognitive Battery Manual. MATRICS Assessment Inc. ; 2006.
 
6) Wechsler D. WAIS-IV : Wechsler Adult Intelligence Scale-Fourth edition. San Antonio, TX : The Psychological Corporation ; 2008/日本版WAIS-IV刊行委員会 (訳). WAISTM-IV知能検査. 日本文化科学社 ; 2018.
 
7) 臺弘ほか. 精神機能のための簡易客観指標. 精神医学 2009 ; 51 : 1173-1184.
 
8) 住吉チカ, 住吉太幹. どのように認知機能を評価するか. 精神科治療学 2015 ; 30 : 1433-1442.
 
9) Wechsler D. WAIS-IV : Wechsler Adult Intelligence Scale-Fourth edition. San Antonio, TX : The Psychological Corporation ; 2008.
 
10) 兼田康弘ほか. 統合失調症認知機能簡易評価尺度日本語版 (BACS-J). 精神医学 2008 ; 50 : 913-917.
 
11) 佐藤拓ほか. MATRICSコンセンサス認知機能評価バッテリーの開発-統合失調症治療への導入を目指して. 臨床精神薬理 2010 ; 13 : 289-296.
 
12) Lin C, 住吉太幹. 統合失調症の認知機能の評価について. 精神医学 2015 ; 57 : 703-712.
 
13) 臺弘. 日常診療のための簡易精神機能テストの実際. 精神科治療学 2003 ; 18 : 965-973.
 
14) 臺弘. 日常臨床のための簡易精神機能テスト (第3報), 分裂病者のバウムテスト. 精神医学 2001 ; 43 : 737-744.
 
15) 臺弘, 三宅由子. 慢性分裂病の機能的亜型分類-反応時間とストレス応答による. 精神医学 1996 ; 39 : 127-132.
 
16) 臺弘, 三宅由子. 日常臨床のための簡易精神生理テスト-特に精神分裂病について. 精神医学 1997 ; 39 : 801-808.
 
17) Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996 ; 153 : 321-330.
PubMed
18) Green MF, et al. Longitudinal studies of cognition and functional outcome in schizophrenia : Implications for MATRICS. Schizophr Res 2004 ; 72 : 41-51.
PubMed
19) Sumiyoshi C, et al. Factors Predicting Work Outcome in Japanese Patients with Schizophrenia : Role of multiple functioning levels. Schizophr Res Cogn 2015 ; 2 : 105-112.
PubMed
20) 住吉チカ. 統合失調症患者における機能的転帰-MATRICS Consensus Cognitive Batteryとの関連. 日本神経精神薬理学雑誌 2011 ; 31 : 251-257.
 
21) Harvey PD, Velligan DI. International assessment of functional skills in people with schizophrenia. Innov Clin Neurosci 2011 ; 8 : 15-18.
PubMed
22) Harvey PD, Strassnig M. Predicting the severity of everyday functional disability in people with schizophrenia : Cognitive deficits, functional capacity, symptoms, and health status. World Psychiatry 2012 ; 11 : 73-79.
PubMed
23) 住吉太幹. 精神疾患における認知機能障害-機能的転帰との関連. 精神科治療学 2015 ; 30 : 1411-1418.
 
24) Burns T, Patrick D. Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatr Scand 2007 ; 116 : 403-418.
PubMed
25) Mausbach BT, et al. A review of instruments for measuring functional recovery in those diagnosed with psychosis. Schizophr Bull 2009 ; 35 : 307-318.
PubMed
26) Green MF, et al. Functional co-primary measures for clinical trials in schizophrenia : Results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry 2008 ; 165 : 221-228.
PubMed
27) Leifker FR, et al. Validating measures of real-world outcome : The results of the VALERO expert survey and RAND panel. Schizophr Bull 2011 ; 37 : 334-343.
PubMed
28) Buchanan RW, et al. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitiveenhancing drugs : What do we know 5 years later? Schizophr Bull 2011 ; 37 : 1209-1217.
 
29) Harvey PD, et al. Latest developments in the matrics process. Psychiatry (Edgmont) 2010 ; 7 : 49-52.
PubMed
30) Harvey PD, et al. Validating the measurement of real-world functional outcomes : Phase I results of the VALERO study. Am J Psychiatry 2011 ; 168 : 1195-1201.
PubMed
31) Heinrichs DW, et al. The Quality of Life Scale : An instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984 ; 10 : 388-398.
PubMed
32) Schneider LC, Struening EL. SLOF : A behavioral rating scale for assessing the mentally ill. Soc Work Res Abstr 1983 ; 19 : 9-21.
 
33) Birchwood M, et al. The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatry 1990 ; 157 : 853-859.
PubMed
34) Wykes T, Sturt E. The measurement of social behaviour in psychiatric patients : An assessment of the reliability and validity of the SBS schedule. Br J Psychiatry 1986 ; 148 : 1-11.
PubMed
35) Velligan DI, et al. The reliability and validity of the Test of Adaptive Behavior in Schizophrenia (TABS). Psychiatry Res 2007 ; 151 : 55-66.
PubMed
36) Rosen A, et al. The life skills profile : A measure assessing function and disability in schizophrenia. Schizophr Bull 1989 ; 15 : 325-337.
PubMed
37) Wallace CJ, et al. The independent living skills survey : A comprehensive measure of the community functioning of severely and persistently mentally ill individuals. Schizophr Bull 2000 ; 26 : 631-658.
PubMed
38) Keefe RS, et al. The Schizophrenia Cognition Rating Scale : An interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. Am J Psychiatry 2006 ; 163 : 426-432.
PubMed
39) Patterson TL, et al. UCSD Performance-Based Skills Assessment : Development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull 2001 ; 27 : 235-245.
PubMed
40) Mausbach BT, et al. Development of a brief scale of everyday functioning in persons with serious mental illness. Schizophr Bull 2007 ; 33 : 1364-1372.
PubMed
41) Bell MD, et al. Clinical benefits of paid work activity in schizophrenia. Schizophr Bull 1996 ; 22 : 51-67.
PubMed
42) McGurk SR, Mueser KT. Cognitive functioning, symptoms, and work in supported employment : A review and heuristic model. Schizophr Res 2004 ; 70 : 147-173.
PubMed
43) Sumiyoshi C, et al. Predicting work outcome in patients with schizophrenia : Influence of IQ decline. Schizophr Res 2018 ; 201 : 172-179.
PubMed
44) Chua YC, et al. First-episode psychosis and vocational outcomes : A predictive model. Schizophr Res 2019 ; 211 : 63-68.
PubMed
45) Keefe RS, Fenton WS. How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr Bull 2007 ; 33 : 912-920.
PubMed
46) 橋本亮太. Research Domain Criteria (RDoC) とその実践-認知機能障害について. 精神科治療学 2017 ; 32 : 419-424.
 
47) 橋本亮太ほか. Research Domain Criteria (RDoC) プロジェクトの概念. 精神医学 2018 ; 60 : 9-16.
 
48) Wechsler D. Wechsler Memory ScaleR-Revised. Pearson/杉下守弘 (日本版作成). 日本版ウェクスラー記憶検査. 日本文化科学社 ; 2001.
 
49) Chan AS, et al. An assessment of the semantic network in patients with Alzheimer's Disease. J Cogn Neurosci 1993 ; 5 : 254-261.
 
50) Bousfield AK, Bousfield WA. Measurement of clustering and of sequential constancies in repeated free recall. Psychol Rep 1966 ; 19 : 935-942.
 
51) Gangarosa ME, et al. New scoring systems for Wechsler Memory Scale : Interrater reliability. J Clin Exp Neuropsychol 1988 ; 2 : 43.
 
52) Paulsen JS, et al. Impairment of the semantic network in schizophrenia. Psychiatry Res 1996 ; 63 (2-3) : 109-121.
 
53) Sumiyoshi C, et al. Disorganization of semantic memory underlies alogia in schizophrenia : An analysis of verbal fluency performance in Japanese subjects. Schizophr Res 2005 ; 74 : 91-100.
PubMed
54) Nohara S, et al. Neural correlates of memory organization deficits in schizophrenia. A single photon emission computed tomography study with 99mTc-ethyl-cysteinate dimer during a verbal learning task. Schizophr Res 2000 ; 42 : 209-222.
PubMed
55) Matsui M, et al. Impairment of story memory organization in patients with schizophrenia. Psychiatry Clin Neurosci 2007 ; 61 : 437-440.
PubMed
56) 住吉チカ. 神経心理学. 日本統合失調症学会 (監修), 福田正人ほか (編), 統合失調症. 医学書院 ; 2013, pp259-274.
 
57) Sumiyoshi C, et al. Semantic Memory Organization in Japanese Patients With Schizophrenia Examined With Category Fluency. Front Psychiatry 2018 ; 9 : 87.
PubMed
58) Sung K, et al. Semantic clustering of category fluency in schizophrenia examined with singular value decomposition. J Int Neuropsychol Soc 2012 ; 18 : 565-575.
PubMed
59) Elvevag B, et al. An automated method to analyze language use in patients with schizophrenia and their first-degree relatives. J Neurolinguistics 2010 ; 23 : 270-284.
PubMed
60) Garrard P, Elvevag B. Language, computers and cognitive neuroscience. Cortex 2014 ; 55 : 1-4.
PubMed
61) Green MF, Nuechterlein KH. The MATRICS initiative : Developing a consensus cognitive battery for clinical trials. Schizophr Res 2004 ; 72 : 1-3.
 
62) Green MF, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia : The NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004 ; 56 : 301-307.
PubMed
63) Nuechterlein KH, et al. The MATRICS Consensus Cognitive Battery, part 1 : Test selection, reliability, and validity. Am J Psychiatry 2008 ; 165 : 203-213.
PubMed
64) Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 2 : co-norming and standardization. Am J Psychiatry 2008 ; 165 : 214-220.
PubMed
倉知正佳. "脳と心" からみた統合失調症の理解. 医学書院 ; 2016.
 
Lezak MD, et al. Neuropsychological Assessment, 5th edition. New York : Oxford University Press ; 2012
 
Strauss E, et al. A Compendium of Neuropsychological Tests, 3ed ed. New York : Oxford University Press ; 2006/秋元波留夫 (監修), 滝川守国ほか (訳). 神経心理学検査法. 創造出版 ; 2004.
 
Mitrushina, MN, et al. Handbook of Normative Data for Neuropsychological Assessment, 2nd ed. New York : Oxford University Press ; 2005.
 
P.81 掲載の参考文献
1) Milev P, et al. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia : A longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005 ; 162 : 495-506.
PubMed
2) Green MF, et al. From perception to functional outcome in schizophrenia : Modeling the role of ability and motivation. Arch Gen Psychiatry 2012 ; 69 : 1216-1224.
PubMed
3) Millan MJ, et al. Negative symptoms of schizophrenia : Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol 2014 ; 24 : 645-692.
PubMed
4) Galderisi S, et al. Negative symptoms of schizophrenia : New developments and unanswered research questions. Lancet Psychiatry 2018 ; 5 : 664-677.
PubMed
5) Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia : Implications for assessment. Schizophr Bull 2006 ; 32 : 238-245.
PubMed
6) Kirkpatrick B, et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006 ; 32 : 214-219.
PubMed
7) Sayers SL, et al. Factor structure and construct validity of the Scale for the Assessment of Negative Symptoms. Psychol Assess 1996 ; 8 : 269-280.
 
8) Strauss GP, et al. The Latent Structure of Negative Symptoms in Schizophrenia. JAMA Psychiatry 2018 ; 75 : 1271-1279.
PubMed
9) Tarbox SI, Pogue-Geile MF. Development of social functioning in preschizophrenia children and adolescents : A systematic review. Psychol Bull 2008 ; 134 : 561-583.
PubMed
10) Evensen J, et al. Flat affect and social functioning : A 10 year follow-up study of first episode psychosis patients. Schizophr Res 2012 ; 139 : 99-104.
PubMed
11) Austin SF, et al. Long-term trajectories of positive and negative symptoms in first episode psychosis : A 10 year follow-up study in the OPUS cohort. Schizophr Res 2015 ; 168 : 84-91.
 
12) Savill M, et al. Do negative symptoms of schizophrenia change over time? A meta-analysis of longitudinal data. Psychol Med 2015 ; 45 : 1613-1627.
 
13) Carpenter WT Jr, et al. Treatment of negative symptoms. Schizophr Bull 1985 ; 11 : 440-452.
PubMed
14) Kirschner M, et al. Secondary negative symptoms - A review of mechanisms, assessment and treatment. Schizophr Res 2017 ; 186 : 29-38.
PubMed
15) Ikemoto S, et al. Basal ganglia circuit loops, dopamine and motivation : A review and enquiry. Behav Brain Res 2015 ; 290 : 17-31.
PubMed
16) Kelley ME, et al. Empirical validation of primary negative symptoms : Independence from effects of medication and psychosis. Am J Psychiatry 1999 ; 156 : 406-411.
PubMed
17) Fervaha G, et al. Antipsychotics and amotivation. Neuropsychopharmacol 2015 ; 40 : 1539-1548.
 
18) Fervaha G, et al. Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia : A positron emission tomography dopamine D2/3 receptor occupancy study. Psychopharmacology (Berl) 2016 ; 233 : 3803-3813.
PubMed
19) Grant PM, Beck AT. Defeatist beliefs as a mediator of cognitive impairment, negative symptoms, and functioning in schizophrenia. Schizophr Bull 2009 ; 35 : 798-806.
PubMed
20) Campellone TR, et al. Defeatist Performance Beliefs, Negative Symptoms, and Functional Outcome in Schizophrenia : A Meta-analytic Review. Schizophr Bull 2016 ; 42 : 1343-1352.
PubMed
21) Rector NA. Dysfunctional attitudes and symptom expression in schizophrenia : Differential associations with paranoid delusions and negative symptoms. J Cogn Psychother 2004 ; 18 : 163-173.
 
22) Brekke J, et al. Biosocial pathways to functional outcome in schizophrenia. Schizophr Res 2005 ; 80 : 213-225.
PubMed
23) Davis L, Brekke J. Social support and functional outcome in severe mental illness : The mediating role of proactive coping. Psychiatry Res 2014 ; 215 : 39-45.
PubMed
24) Ohshima I, et al. Effects of environmental deprivation on negative symptoms of schizophrenia : A nationwide survey in Japan's psychiatric hospitals. Psychiatry Res 2005 ; 136 : 163-171.
 
25) Peralta V, Cuesta MJ. Dimensional structure of psychotic symptoms : An item-level analysis of SAPS and SANS symptoms in psychotic disorders. Schizophr Res 1999 ; 38 : 13-26.
PubMed
26) Kirkpatrick B, et al. The brief negative symptom scale : Psychometric properties. Schizophr Bull 2011 ; 37 : 300-305.
PubMed
27) Strauss GP, Gold JM. A new perspective on anhedonia in schizophrenia. Am J Psychiatry 2012 ; 169 : 364-373.
PubMed
28) Kring AM, Barch DM. The motivation and pleasure dimension of negative symptoms : Neural substrates and behavioral outputs. Eur Neuropsychopharmacol 2014 ; 24 : 725-736.
PubMed
29) Fusar-Poli P, et al. Treatments of Negative Symptoms in Schizophrenia : Meta-Analysis of 168 Randomized Placebo-Controlled Trials. Schizophr Bull 2015 ; 41 : 892-899.
PubMed
30) Cunningham ODG, Johnstone EC. Treatment and management of schizophrenia. In : Gelder MG, et al (eds). New Oxford Textbook of Psychiatry, 2nd ed. Oxford University Press ; 2012, pp578-595.
 
31) Velthorst E, et al. Adapted cognitive-behavioural therapy required for targeting negative symptoms in schizophrenia : Meta-analysis and meta-regression. Psychol Med 2015 ; 45 : 453-465.
PubMed
32) Grant PM, et al. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia. Arch Gen Psychiatry 2012 ; 69 : 121-127.
PubMed
33) van Eck RM, et al. The Relationship Between Clinical and Personal Recovery in Patients With Schizophrenia Spectrum Disorders : A Systematic Review and Meta-analysis. Schizophr Bull 2018 ; 44 : 631-642.
PubMed
34) 橋本直樹 (監訳). 簡易陰性症状評価尺度-スコアシートおよびワークブック. 私信, 2018.
 
Foussias G, et al. Negative symptoms of schizophrenia : Clinical features, relevance to real world functioning and specificity versus other CNS disorders. Eur Neuropsychopharmacol 2014 ; 24 : 693-709.
PubMed
Kirkpatrick B, et al. Primary, Enduring Negative Symptoms : An Update on Research. Schizophr Bull 2017 ; 43 : 730-736.
PubMed
池淵恵美. 「陰性症状」再考-統合失調症のリカバリーに向けて. 精神経誌 2015 ; 117 (3) : 179-194.
 
Lincoln TM, et al. Current developments and challenges in the assessment of negative symptoms. Schizophr Res 2017 ; 186 : 8-18.
PubMed
Waltz JA, Gold JM. Motivational Deficits in Schizophrenia and the Representation of Expected Value. Curr Topics Behav Neurosci 2016 ; 27 : 375-410. In : Simpson EH, Balsam PD (eds). Behavioral Neuroscience of Motivation. Springer, 2016.
 
P.91 掲載の参考文献
1) Prince M, et al. No health without mental health. Lancet 2007 ; 370 (9590) : 859-877.
PubMed
2) Salomon JA, et al. Common values in assessing health outcomes from disease and injury : Disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012 ; 380 (9859) : 2129-2143.
PubMed
3) Galletly C, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 2016 ; 50 (5) ; 410-472.
PubMed
4) Haahr U, et al. First-episode psychosis : Diagnostic stability over one and two years. Psychopathology 2008 ; 41 (5) : 322-329.
PubMed
5) Perkins DO, et al. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia : A critical review and meta-analysis. Am J Psychiatry 2005 ; 162 (10) : 1785-1804.
PubMed
6) Ito S, et al. Differential impacts of duration of untreated psychosis (DUP) on cognitive function in first-episode schizophrenia according to mode of onset. Eur Psychiatry 2015 ; 30 (8) : 995-1001.
PubMed
7) Birchwood M, et al. Early intervention in psychosis : The critical period hypothesis. Br J Psychiatry Suppl 1998 ; 172 (33) : 53-59.
PubMed
8) Takahashi T, Suzuki M. Brain morphologic changes in early stages of psychosis : Implications for clinical application and early intervention. Psychiatry Clin Neurosci 2018 ; 72 (8) : 556-571.
PubMed
9) Melle I, et al. Prevention of negative symptom psychopathologies in first-episode schizophrenia : Twoyear effects of reducing the duration of untreated psychosis. Arch Gen Psychiatry 2008 ; 65 (6) : 634-640.
 
10) Secher RG, et al. Ten-year follow-up of the OPUS specialized early intervention trial for patients with a first episode of psychosis. Schizophr Bull 2015 ; 41 (3) : 617-626.
PubMed
11) Conrad K. Die beginnende Schizophrenie-Versuch einer Gestaltanalyse des Wahns. Stuttgart : George Thieme Verlag ; 1966/山口直彦ほか (訳). 分裂病のはじまり-妄想のゲシュタルト分析の試み. 岩崎学術出版社 ; 1994.
 
12) Schultze-Lutter F. Subjective symptoms of schizophrenia in research and the clinic : The basic symptom concept. Schizophr Bull 2009 ; 35 (1) : 5-8.
PubMed
13) 中安信夫ほか. 初期症状. 松下正明 (総編集), 臨床精神医学講座 2, 精神分裂病 I. 中山書店 ; 1999, pp313-348.
 
14) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd edition. American Psychiatric Association ; 1980/高橋三郎ほか (訳). DSM-III 精神障害の分類と診断の手引き. 医学書院 ; 1982.
 
15) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition. American Psychiatric Association ; 2013/日本精神神経学会 <日本語版用語監修>, 高橋三郎ほか (監訳). DSM-5 精神疾患の診断・統計マニュアル. 医学書院 ; 2014.
 
16) World Health Organization. International Classification of Diseases 11th Revision. https://icd.who.int/en/
PubMed
17) Yung AR, McGorry PD. The prodromal phase of first-episode psychosis : Past and current conceptualizations. Schizophr Bull 1996 ; 22 (2) : 353-370.
PubMed
18) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition. American Psychiatric Association ; 1994.
 
19) Zoghbi AW, et al. Schizotypal personality disorder in individuals with the Attenuated Psychosis Syndrome : Frequent co-occurrence without an increased risk for conversion to threshold psychosis. J Psychiatric Res 2019 ; 114 : 88-92.
PubMed
20) 原田誠一, 岡崎祐士. 精神分裂病ハイリスク児研究と病前特徴の研究. 松下正明 (総編集), 臨床精神医学講座 2, 精神分裂病 I. 中山書店 ; 1999, pp97-115.
 
21) Johnstone EC, et al. Predicting schizophrenia : Findings from the Edinburgh High-Risk Study. Br J Psychiatry 2005 ; 186 : 18-25.
PubMed
22) Cornblatt B, et al. The schizophrenia prodrome : Treatment and high-risk perspectives. Schizophr Res 2002 ; 54 (1-2) : 177-186.
 
23) Yung AR, et al. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull 1996 ; 22 (2) : 283-303.
PubMed
24) Yung AR, et al. Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl 1998 ; 172 (33) : 14-20.
PubMed
25) Fusar-Poli P, et al. Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk : A Metaanalytical Stratification. JAMA Psychiatry 2016 ; 73 (2) : 113-120.
 
26) Yung AR, et al. Mapping the onset of psychosis : The Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry 2005 ; 39 (11-12) : 964-971.
 
27) Miller TJ, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms : Predictive validity, interrater reliability, and training to reliability. Schizophr Bull 2003 ; 29 (4) : 703-715.
PubMed
28) Schultze-Lutter F, et al. Basic symptoms and the prediction of first-episode psychosis. Curr Pharm Des 2012 ; 18 (4) : 351-357.
PubMed
29) Mizuno M, et al. Clinical practice and research activities for early psychiatric intervention at Japanese leading centres. Early Interv Psychiatry 2009 ; 3 (1) : 5-9.
PubMed
30) International Early Psychosis Association Writing Group. International clinical practice guidelines for early psychosis. Br J Psychiatry Suppl 2005 ; 187 (48) : s120-s124.
 
31) 桂雅宏ほか. ARMSへの早期介入-議論の整理と海外ガイドラインの紹介. 精神医学 2016 ; 58 (7) : 571-579.
 
32) Fusar-Poli P, et al. Predicting psychosis : Meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 2012 ; 69 (3) : 220-229.
PubMed
33) Fusar-Poli P, et al. At risk for schizophrenic or affective psychoses? : A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. Schizophr Bull 2013a ; 39 (4) : 923-932.
 
34) Jackson HJ, McGorry PD. Recognition and Management of Early Psychosis : A Preventive Approach, 2nd edition. Cambridge University Press ; 2009/Yung A, et al. ARMSと予測. 水野雅文ほか (監訳). 早期精神病の診断と治療. 医学書院 ; 2010, pp80-102.
 
35) McGorry PD, et al. Clinical staging of psychiatric disorders : A heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 2006 ; 40 (8) : 616-622.
PubMed
36) Fusar-Poli P, et al. Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state : Impact on psychopathology and transition to psychosis. Schizophr Bull 2014 ; 40 (1) : 120-131.
 
37) Takahashi T, et al. Quality of life in individuals with attenuated psychotic symptoms : Possible role of anxiety, depressive symptoms, and socio-cognitive impairments. Psychiatry Res 2017 ; 257 : 431-437.
PubMed
38) Addington J, et al. At clinical high risk for psychosis : Outcome for nonconverters. Am J Psychiatry 2011 ; 168 (8) : 800-805.
PubMed
39) Lin A, et al. Outcomes of nontransitioned cases in a sample at ultra-high risk for psychosis. Am J Psychiatry 2015 ; 172 (3) : 249-258.
 
40) Jackson HJ, McGorry PD. Recognition and Management of Early Psychosis : A Preventive Approach, 2nd edition. Cambridge University Press, 2009/Pantelis C, et al. 精神病および統合失調症の神経生物学的エンドフェノタイプ-疾患発症の生物学的マーカーはあるか? 水野雅文ほか (監訳). 早期精神病の診断と治療. 医学書院 ; 2010, pp58-77.
 
41) Fusar-Poli P, et al. The psychosis high-risk state : A comprehensive state-of-the-art review. JAMA Psychiatry 2013b ; 70 (1) : 107-120.
 
42) Koutsouleris N, et al. Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. Arch Gen Psychiatry 2009 ; 66 (7) : 700-712.
PubMed
43) Koutsouleris N, et al. Prediction models of functional outcomes for individuals in the clinical high-risk state for psychosis or with recent-onset depression : A multimodal, multisite machine learning analysis. JAMA Psychiatry 2018 ; 75 (11) : 1156-1172.
PubMed
44) van Os J, et al. A systematic review and meta-analysis of the psychosis continuum : Evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med 2009 ; 39 (2) : 179-195.
PubMed
45) Nishida A, et al. Associations between psychotic-like experiences and mental health status and other psychopathologies among Japanese early teens. Schizophr Res 2008 ; 99 (1-3) : 125-133.
PubMed
46) Poulton R, et al. Children's self-reported psychotic symptoms and adult schizophreniform disorder : A 15-year longitudinal study. Arch Gen Psychiatry 2000 ; 57 (11) : 1053-1058.
 
水野雅文ほか. 早期精神病の診療プランと実践例-予備的ガイダンス 2017. http://www.jseip.jp/top/document
 
Jackson HJ, McGorry PD. Recognition and Management of Early Psychosis : A Preventive Approach, 2nd edition. Cambridge University Press ; 2009/水野雅文ほか (監訳). 早期精神病の診断と治療. 医学書院 ; 2010.
 
藤井千代, 水野雅文. 早期介入の臨床倫理. 臨床精神医学 2012 ; 41 (10) : 1387-1394.
Medical*Online
倉知正佳. "脳と心" からみた統合失調症の理解. 医学書院 ; 2016.
 
Nelson B, et al. Long-term follow-up of a group at ultra high risk ("prodromal") for psychosis : The PACE 400 study. JAMA Psychiatry 2013 ; 70 (8) : 793-802.
PubMed
P.101 掲載の参考文献
1) Sado M, et al. The cost of schizophrenia in Japan. Neuropsychiatr Dis Treat 2013 ; 9 : 787-798.
PubMed
2) 根本隆洋ほか. 初回エピソード統合失調症. 精神医学 2016 ; 58 : 563-570.
 
3) 根本隆洋. 統合失調症発症以前への支援. こころの科学 2011 ; 160 : 71-77.
 
4) Fusar-Poli P, et al. Predicting psychosis : Meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 2012 ; 69 : 220-229.
PubMed
5) Fusar-Poli P, et al. At risk for schizophrenia or affective psychosis? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. Schizophr Bull 2013 ; 39 : 923-932.
 
6) Fusar-Poli P, et al. Cognitive functioning in prodromal psychosis : A meta-analysis. Arch Gen Psychiatry 2012 ; 69 : 562-571.
PubMed
7) 根本隆洋. 精神病早期段階における病識と介入・支援. 精神医学 2019 ; 61 (12) : 1437-1445.
 
8) Marshall M, et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients : A systematic review. Arch Gen Psychiatry 2005 ; 62 : 975-983.
PubMed
9) Ito S, et al. Differential impacts of duration of untreated psychosis (DUP) on cognitive function in first-episode schizophrenia according to mode of onset. Eur Psychiatry 2015 ; 30 : 995-1001.
PubMed
10) 松本和紀ほか. サイコーシス早期段階におけるCBTの活用. 精神経誌 2013 ; 115 : 390-398.
 
11) Kane JM, et al. The RAISE early treatment program for first-episode psychosis : Background, rationale, and study design. J Clin Psychiatry 2015 ; 76 : 240-246.
PubMed
12) Leucht S, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia : A systematic review and meta-analysis. Lancet 2012 ; 379 : 2063-2071.
PubMed
13) 日本精神保健・予防学会. 早期精神病の診療プランと実践例-予備的ガイダンス 2017 (Treatment Plans and Implementation for Early Psychosis : Preliminary Guidance 2017). http://www.jseip.jp/top/document
 
14) 根本隆洋. 精神疾患の予防-20年の到達点と今後の展望. 早期精神病に特化したデイケアサービスの取り組みと今後. 日本社会精神医学会雑誌 2018 ; 27 (1) : 59-63.
 
15) 根本隆洋. 精神疾患の早期段階におけるデイケアサービスとその意義. デイケア実践研究 2017 ; 21 (1) : 87-90.
Medical*Online
16) Kessler RC, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arc Gen Psychiatry 2005 ; 62 (6) : 593-602.
 
17) 水野雅文ほか. 地域ケアの時代における精神疾患-早期発見・早期支援の課題と可能性. 精神医学 2015 ; 57 (2) : 89-103.
 
18) Rickwood D, et al. Australia's innovation in youth mental health care : The headspace centre model. Early Interv Psychiatry 2019 ; 13 (1) : 159-166.
 
19) MEICISホームページ. https://meicis.jp/
 
20) SODAホームページ. https://soda.tokyoadachi.com/
 
P.110 掲載の参考文献
1) Institute of Medicine (US) Committee to Advise the Public Health Service on Clinical Practice Guidelines ; Field MJ, et al (eds). Clinical Practice Guidelines : Directions for a New Program [Internet]. Washington DC : National Academies Press ; 1990. p143.
 
2) 小島原典子ほか (編). Minds診療ガイドライン作成マニュアル 2017. 公益財団法人日本医療機能評価機構 ; 2017.
 
3) Woolf SH, et al. Clinical guidelines : Potential benefits, limitations, and harms of clinical guidelines. BMJ 1999 ; 318 (7182) : 527-530.
PubMed
4) Cluzeau F, et al. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines : The AGREE project. Qual Saf Heal Care 2003 ; 12 (1) : 18-23.
 
5) Brouwers MC, et al. AGREE II : Advancing guideline development, reporting and evaluation in health care. CMAJ 2010 ; 182 (18) : E839-842.
PubMed
6) 公益財団法人日本医療機能評価機構. AGREE II (The Appraisal of Guidelines for Research and Evaluation II) 日本語訳. Internet. https://minds.jcqhc.or.jp/s/evaluation_tool [cited 2020 Jan 6]
 
7) Gaebel W, et al. Schizophrenia practice guidelines : International survey and comparison. Br J Psychiatry 2005 ; 187 : 248-255.
PubMed
8) Gaebel W, et al. Schizophrenia guidelines across the world : A selective review and comparison. Int Rev Psychiatry 2011 ; 23 (4) : 379-387.
PubMed
9) キセイン リー・アンドリューほか. 英国の精神医療におけるNICEガイドラインの影響. 精神経誌 2017 ; 119 (3) : 166-172.
 
10) National Institute for Health and Care Excellence. Developing NICE guidelines : The manual. Process and methods guides. 2014.
PubMed
11) National Institute for Health and Clinical Excellence. Psychosis and schizophrenia in adults : THE NICE Guideline on Treatment and Management. 2014.
 
12) National Institute for Health and Care Excellence. Psychosis and schizophrenia overview. https://pathways.nice.org.uk/pathways/psychosis-and-schizophrenia [cited 2019 Jan 6]
 
13) American Psychiatric Association. PRACTICE GUIDELINE FOR THE Treatment of Patients With Schizophrenia Second Edition. 2004. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/schizophrenia.pdf
 
14) McDonagh MS, et al. Treatments for Schizophrenia in Adults : A Systematic Review. Comparative Effectiveness Reviews 2017.
PubMed
15) Canadian Psychiatric Association. Clinical Practice Guidelines. Treatment of Schizophrenia. Can J Psychiatry 2005 ; 50 (13 Suppl 1) : 7S-57S.
 
16) Pringsheim T, Addington D. Canadian Schizophrenia Guidelines : Introduction and Guideline Development Process. Can J Psychiatry 2017 ; 62 (9) : 586-593.
PubMed
17) The ADAPTE Collaboration. The ADAPTE Process : Resource Toolkit for Guideline Adaptation. Version 2.0. 2009. p95.
 
18) Galletly C, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 2016 ; 50 : 410-472.
PubMed
19) Cuijpers P. Targets and outcomes of psychotherapies for mental disorders : An overview. World Psychiatry 2019 ; 18 (3) : 276-285.
PubMed
20) Bighelli I, et al. Are Randomized Controlled Trials on Pharmacotherapy and Psychotherapy for Positive Symptoms of Schizophrenia Comparable? A Systematic Review of Patient and Study Characteristics. Schizophr Bull [Internet] 2019 ; 1-9.
 
21) Morrison AP, et al. Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis : A randomised controlled pilot and feasibility study. Lancet Psychiatry [Internet] 2018 ; 5 (5) : 411-423.
PubMed
22) Morrison AP. Should people with psychosis be supported in choosing cognitive therapy as an alternative to antipsychotic medication : A commentary on current evidence. Schizophr Res 2019 ; 203 : 94-98.
PubMed
P.118 掲載の参考文献
1) Slade M. 100 ways to support recovery 2nd editon : A guide for mental health professionals. London : Rethink Mental Illness ; 2013.
 
2) 精神保健従事者のためのガイド「本人のリカバリー100の支え方」. http://npsy.umin.jp/~npsy/cgi-bin/wordpress/wp-content/themes/tokyo_univ/pdf/Japanese_version_of_100_Ways_To_Support_Recovery.pdf
 
3) Anthony WA. Recovery from mental illness : The guiding vision of the mental health service system in the 1990s. Psychosocial Rehabilitation Journal 1993 ; 16 (4) : 11-23.
 
4) 福田正人ほか. 統合失調症リカバリー支援ガイド-当事者・家族・専門職それぞれの主体的人生のための共同創造 (第1.1版). https://psychiatry.dept.med.gunma-u.ac.jp/wordpress/wp-content/uploads/2020/04/shienguide1-1.pdf
 
5) Fulford KWM (Bill), et al. Essential Values-Based Practice : Clinical Stories Linking Science with People. Cambridge University Press ; 2012/大西弘高・尾藤誠司 (監訳). 価値に基づく診療 VBP実践のための10のプロセス. メディカルサイエンス インターナショナル ; 2016.
 
6) 尾藤誠司. value-based practice (VBP) とは何か? Medical Practce 2019 ; 36 (11) : 1658-1665.
 
7) 笠井清登. 統合失調症. 長谷川寿一 (監修), 笠井清登ほか (編), 思春期学. 東京大学出版会 ; 2015, pp219-229.
 
8) 笠井清登. 統合失調症-脳と生活と思春期発達の交点. 日本統合失調症学会 (監修), 福田正人ほか (編), 統合失調症. 医学書院 ; 2013, pp51-58.
 
P.127 掲載の参考文献
1) 日本神経精神薬理学会 (編). 統合失調症薬物治療ガイドライン. 医学書院 ; 2016.
 
2) 稲垣中, 稲田俊也. 新規抗精神病薬の等価換算 (その7) -Asenapine. 臨床精神薬理 2017 ; 20 : 89-97.
 
3) Kusumi I, et al. Psychopharmacology of atypical antipsychotic drugs : From the receptor binding profile to neuroprotection and neurogenesis. Psychiatry Clin Neurosci 2015 ; 69 : 243-258.
PubMed
4) Shahid M, et al. Asenapine : A novel psychopharmacologic agents with a unique human receptor signature. J Psychopharmacol 2009 ; 23 : 65-73.
 
5) Maeda K, et al. Brexpiprazole I : In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 2014 ; 350 : 589-604.
PubMed
6) 久住一郎, 小山司. カタトニア (緊張病) 症候群. 堀口淳 (編), 脳とこころのプライマリケア 6. 幻覚と妄想. シナジー ; 2011, pp365-373.
 
7) 吉村文太, 石津すぐる. 緊張型統合失調症24例に対するquetiapineの使用経験-統合失調症における緊張病性昏迷に対する薬物療法の有効性について考える. 臨床精神薬理 2008 ; 11 : 2265-2276.
 
8) 橋本直樹ほか. 統合失調症における認知機能障害. 精神科 2019 ; 34 : 214-219.
 
9) Keefe RS, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch gen Psychiatry 2007 ; 64 : 633-647.
PubMed
10) Ogino S, et al. Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011 ; 35 : 78-83.
PubMed
11) Kitajima R, et al. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic. Prog Neuropsychopharmacol Biol Psychiatry 2012 ; 36 : 300-306.
PubMed
12) Wykes T, et al. A meta-analysis of cognitive remediation for schizophrenia : Methodology and effect sizes. Am J Psychiatry 2011 ; 168 : 472-485.
PubMed
13) 竹内啓善. 抗精神病薬の用量と認知機能. 臨床精神薬理 2015 ; 18 : 1549-1558.
 
14) Vita A, et al. Predictors of cognitive and functional improvement and normalization after cognitive remediation in patients with schizophrenia. Schizophr Res 2013 ; 150 : 51-57.
PubMed
15) Vinogradov S, et al. The cognitive cost of anticholinergic burden : Decreased response to cognitive training in schizophrenia. Am J Psychiatry 2009 ; 166 : 1055-1062.
PubMed
16) Lausen TM, et al. Excess early mortality in schizophrenia. Annu Rev Clin Psychol 2014 ; 10 : 425-448.
 
17) Tiihonen J, et al. 11-year follow-up of mortality in patients with schizophrenia : A population-based cohort study (FIN11 study). Lancet 2009 ; 374 : 620-627.
PubMed
18) Ifteni P, et al. Sudden unexpected death in schizophrenia : Autopsy findings in psychiatric inpatients. Schizophr Res 2014 ; 155 : 72-76.
PubMed
19) Sweeting J, et al. Postmortem analysis of cardiovascular deaths in schizophrenia : A 10-year review. Schizophr Res 2013 ; 150 : 398-403.
PubMed
20) Manu P, et al. Sudden deaths in psychiatric patients. J Clin Psychiatry 2011 ; 72 : 936-941.
PubMed
21) Sugai T, et al. High Prevalence of Obesity, Hypertension, Hyperlipidemia, and Diabetes Mellites in Japanese Outpatients with Schizophrenia : A Nationwide Survey. PLoS One 2016 ; 11 : e0166429.
 
22) Sugai T, et al. Difference in prevalence of metabolic syndrome between Japanese outpatients and inpatients with schizophrenia : A nationwide survey. Schizophr Res 2016 ; 171 : 68-73.
PubMed
23) American Diabetes Association, et al. Consensus development conference on antipsychotics drugs and obesity and diabetes. Diabetes Care 2004 ; 27 : 596-601.
PubMed
24) Stubbs B, et al. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia : A systematic review and comparative meta-analysis. Acta Psychiatr Scand 2015 ; 132 : 144-157.
PubMed
25) Braceland FJ, et al. Delayed action of insulin in schizophrenia. Am J Psychiatry 1945 ; 102 : 108-110.
 
26) Ryan MCM, et al. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003 ; 160 : 284-289.
 
27) Hansen T, et al. At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol Psychiatry 2011 ; 70 : 59-63.
PubMed
28) Kirkpatrick B. Schizophrenia as a systemic disease. Schizophr Bull 2009 ; 35 : 381-382.
PubMed
29) 藤井康男. ゼプリオン投与中の死亡例から, 我々はなにを学ぶべきか? 臨床精神薬理 2014 ; 17 : 1395-1418.
 
30) Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006 ; 51 : 492-501.
PubMed
31) De Nayer A, et al. Belgian consensus on metabolic problems associated with atypical antipsychotics. Int J Psychiatry Clin Pract 2005 ; 9 : 130-137.
PubMed
32) Expert group. 'Schizophrenia and Diabetes 2003' Expert Consensus Meeting, Dublin. 3-4 October 2003 : consensus summary. Br J Psychiatry Suppl 2004 ; 47 : S112-114.
 
33) Haupt DW, et al. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 2009 ; 166 : 345-353.
PubMed
34) Lambert TJ, et al. Diabetes, psychotic disorders and antipsychotic therapy : A consensus statement. Med J Aust 2004 ; 181 : 544-548.
PubMed
35) Marder SR, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004 ; 161 : 1334-1349.
PubMed
36) Woo V, et al. Canadian Diabetes Association : Position paper : Antipsychotic Medication and Association Risks of Weight Gain Diabetes. Can J Diabetes 2005 ; 29 : 111-112.
 
37) 久住一郎. 抗精神病薬使用時の血糖モニタリングの頻度はどう考えるべきか? 精神科治療学 2018 ; 33 : 549-554.
 
38) 村崎光邦ほか. 第二世代 (非定型) 抗精神病薬を投与する際の血糖モニタリングガイダンスの提案. 臨床精神薬理 2008 ; 11 : 1139-1148.
 
39) Kusumi I, et al. Predictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorder. BJPsych Open 2018 ; 4 : 454-460.
PubMed
40) Kusumi I, et al. Screening for diabetes using monitoring guidance in schizophrenia patients treated with second-generation antipsychotics : A 1-year follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 2011 ; 35 : 1922-1926.
PubMed
41) Kane JM, et al. Non-adherence to medication in patients with psychotic disorders : Epidemiology, contributing factors and management strategies. World Psychiatry 2013 ; 12 : 216-226.
PubMed
42) Kishimoto T, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia : A meta-analysis of randomized trails. Schizophr Bull 2014 ; 40 : 192-213.
 
43) Kishimoto T, et al. Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients with Schizophrenia : A Meta-analysis of Prospective and Retrospective Cohort Studies. Schizophr Bull 2018 ; 44 : 603-619.
PubMed
44) Schreiner A, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res 2015 ; 169 : 393-399.
PubMed
45) Subotnik KL, et al. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial. JAMA Psychiatry 2015 ; 72 : 822-829.
PubMed
46) Seeman P. Atypical antipsychotics : Mechanism of action. Can J Psychiatry 2002 ; 47 : 27-38.
PubMed
47) 久住一郎, 小山司. 統合失調症再発予防効果におけるドパミンの役割. 臨床精神薬理 2008 ; 11 : 1451-1456.
 
48) 内田裕之. 抗精神病薬によるドパミンD2受容体の持続的遮断と非持続的遮断. 臨床精神薬理 2019 ; 22 : 341-346.
 
49) Kusumi I, et al. Long-term perospirone treatment with a single dose at bedtime in schizophrenia : Relevant to intermittent dopamine D2 receptor antagonism. Prog Neuro-Psychopharmacol Biol Psychiatry 2008 ; 32 : 520-522.
 
P.138 掲載の参考文献
1) Tarrier N, et al. A trial of two cognitive-behavioural methods of treating drug-resistant residual psychotic symptoms in schizophrenic patients : I. Outcome. Br J Psychiatry 1993 ; 162 : 524-532.
PubMed
2) Psychosis and schizophrenia in adults : Prevention and management. National Institute for Health and Care Excellence ; 2014.
 
3) 石垣琢麿. 統合失調症の認知行動療法 (CBTp) -CBTpの概略と欧米における現状. 精神経誌 2013 ; 115 (4) : 372-378.
 
4) Kingdon DG, Turkington D. Cognitive-Behavioural Therapy of Schizophrenia. New York : Guilford Press ; 1994/原田誠一 (訳). 統合失調症の認知行動療法. 日本評論社 ; 2002.
 
5) Morrison AP. A manualised treatment protocol to guide delivery of evidence-based cognitive therapy for people with distressing psychosis : Learning from clinical trials. Psychosis 2017 ; 9 (3) : 271-281.
 
6) Beck AT, et al. Schizophrenia : Cognitive Theory, Research, and Therapy. New York : Guilford ; 2009/大野裕 (監訳). ベックの統合失調症の認知療法. 岩崎学術出版社 ; 2018.
 
7) Beck AT. Cognitive Therapy and the Emotional Disorders. New York : International Universities Press ; 1976.
 
8) Hazell CM, et al. A systematic review and meta-analysis of low intensity CBT for psychosis. Clin Psychol Rev 2016 ; 45 : 183-192.
PubMed
9) Wong AWS, et al. Group cognitive behavioural therapy for Chinese patients with psychotic disorder : A feasibility controlled study. Asian J Psychiatr 2019 ; 39 : 157-164.
PubMed
10) Louise S, et al. Mindfulness- and acceptance-based interventions for psychosis : Our current understanding and a meta-analysis. Schizophr Res 2018 ; 192 : 57-63.
 
11) 松本和紀. 精神病性障害に対する認知行動療法. 精神医学 2017 ; 59 (5) : 467-473.
 
12) French P, Morrison AP. Early Detection and Cognitive Therapy for People at High Risk of Developing Psychosis : A Treatment Approach. Hoboken, NJ : John Wiley & Sons, Ltd ; 2004/松本和紀, 宮腰哲生 (訳). 統合失調症の早期発見と認知療法-発症リスクの高い状態への治療的アプローチ. 星和書店 ; 2006.
 
13) Fowler D, et al. Cognitive Behaviour Therapy for Psychosis : Theory and Practice. Hoboken, NJ : John Wiley and Sons ; 1995/石垣琢麿, 丹野義彦 (監訳). 統合失調症を理解し支援するための認知行動療法. 金剛出版 ; 2011.
 
14) Wykes T, et al. Cognitive behavior therapy for schizophrenia : Effect sizes, clinical models, and methodological rigor. Schizophr Bull 2008 ; 34 (3) : 523-537.
PubMed
15) Jauhar S, et al. Cognitive-behavioural therapy for the symptoms of schizophrenia : Systematic review and meta-analysis with examination of potential bias. Br J Psychiatry 2014 ; 204 (1) : 20-29.
PubMed
16) Bighelli I, et al. Psychological interventions to reduce positive symptoms in schizophrenia : Systematic review and network meta-analysis. World Psychiatry 2018 ; 17 (3) : 316-329.
PubMed
17) Bighelli I, et al. Response rates in patients with schizophrenia and positive symptoms receiving cognitive behavioural therapy : A systematic review and single-group meta-analysis. BMC Psychiatry 2018 ; 18 (1) : 380.
PubMed
18) McKenna P, et al. The controversy about cognitive behavioural therapy for schizophrenia. World Psychiatry 2019 ; 18 (2) : 235-236.
PubMed
19) 国立研究開発法人日本医療研究開発機構 (AMED) 障害者対策総合研究開発事業 (精神障害分野). 早期精神病の診療プランと実践例-予備的ガイダンス 2017. (研究開発代表者 : 水野雅文). 2017.
 
20) Matsumoto K, et al. Federated multi-site longitudinal study of at-risk mental state for psychosis in Japan. Schizophr Res 2019 ; 204 : 343-352.
PubMed
21) Stafford MR, et al. Early interventions to prevent psychosis : Systematic review and meta-analysis. BMJ 2013 ; 346 : f185.
PubMed
22) Matsumoto K, et al. Open-label study of cognitive behavioural therapy for individuals with at-risk mental state : Feasibility in the Japanese clinical setting. Early Interv Psychiatry 2019 ; 13 (1) : 137-141.
PubMed
23) 松本和紀ほか. ARMS (アットリスク精神状態) に対する認知行動療法の現状. 最新精神医学 2018 ; 23 (2) : 105-112.
Medical*Online
24) Grant PM, et al. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia. Arch Gen Psychiatry 2012 ; 69 (2) : 121-127.
PubMed
25) Birchwood M, et al. Cognitive behaviour therapy to prevent harmful compliance with command hallucinations (COMMAND) : A randomised controlled trial. Lancet Psychiatry 2014 ; 1 (1) : 23-33.
PubMed
26) Byrne S, et al. A Casebook of Cognitive Behavior Therapy for Command Hallucinations : A Social Rank Theory Approach. London : Routledge ; 2006/菊池安希子 (監訳). 命令幻聴の認知行動療法. 星和書店 ; 2010.
 
27) de Bont PA, et al. Prolonged exposure and EMDR for PTSD v. a PTSD waiting-list condition : Effects on symptoms of psychosis, depression and social functioning in patients with chronic psychotic disorders. Psychol Med 2016 ; 46 (11) : 2411-2421.
 
28) Morrison AP, et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs : A single-blind randomised controlled trial. Lancet 2014 ; 383 (9926) : 1395-1403.
 
29) Morrison AP, et al. Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis : A randomised controlled pilot and feasibility study. Lancet Psychiatry 2018 ; 5 (5) : 411-423.
PubMed
30) Kuller AM, et al. Cognitive behavioral therapy and schizophrenia : A survey of clinical practices and views on efficacy in the United States and United kingdom. Community Ment Health J 2010 ; 46 (1) : 2-9.
PubMed
31) Turkington D, et al. Outcomes of an effectiveness trial of cognitive-behavioural intervention by mental health nurses in schizophrenia. Br J Psychiatry 2006 ; 189 : 36-40.
PubMed
32) Chadwick P, et al. Cognitive Therapy for Delusions, Voices and Paranoia. Hoboken, NJ : John Wiley & Sons ; 1996/古村健, 石垣琢麿 (訳). 妄想・幻声・パラノイアへの認知行動療法. 星和書店 ; 2012.
 
33) 石垣琢磨ほか. 事例で学ぶ統合失調症のための認知行動療法. 金剛出版 ; 2019.
 
34) 石垣琢磨. メタ認知トレーニング (MCT) の概要と有効性. 最新精神医学 2015 ; 20 (2) : 125-130.
 
35) 菊池安希子, 美濃由紀子. 国立精神・神経センター・医療観察法病棟が, そのプログラムとノウハウを公開します その1 まずは治療プログラムの枠組みを紹介します. 精神看護 2010 ; 13 (1) : 69-74.
 
36) 石垣琢磨. メタ認知トレーニング (Metacognitive Training ; MCT) 日本語版の開発. 精神医学 2012 ; 54 (9) : 939-947.
 
37) Moritz S, et al. Metacognitive Training for Psychosis (MCT). Manual. six volume, version 6.3. VanHam Campus Press ; 2010.
 
38) Moritz S, Woodward TS. Metacognitive training in schizophrenia : From basic research to knowledge translation and intervention. Curr Opin Psychiatry 2007 ; 20 (6) : 619-625.
PubMed
39) Moritz S, et al. Sowing the seeds of doubt : A narrative review on metacognitive training in schizophrenia. Clin Psychol Rev 2014 ; 34 (4) : 358-366.
 
石垣琢磨ほか. 事例で学ぶ統合失調症のための認知行動療法. 金剛出版 ; 2019.
 
Kingdon DG, Turkington D. Cognitive-behavioural Therapy of Schizophrenia. New York : Guilford Press ; 1994/原田誠一 (訳). 統合失調症の認知行動療法. 日本評論社 ; 2002.
 
Beck AT, et al. Schizophrenia : Cognitive Theory, Research, and Therapy. New York : Guilford Press ; 2009/大野裕 (監訳). ベックの統合失調症の認知療法. 岩崎学術出版社 ; 2018.
 
French P, Morrison AP. Early Detection and Cognitive Therapy for People at High Risk of Developing Psychosis : A Treatment Approach. Hoboken, NJ : John Wiley & Sons, Ltd ; 2004/松本和紀, 宮腰哲生 (訳). 統合失調症の早期発見と認知療法-発症リスクの高い状態への治療的アプローチ. 星和書店 ; 2006.
 
Morrison AP. A manualised treatment protocol to guide delivery of evidence-based cognitive therapy for people with distressing psychosis : Learning from clinical trials. Psychosis 2017 ; 9 (3) : 271-281.
 
P.145 掲載の参考文献
1) 臺弘ほか (編). 分裂病の生活臨床. 創造出版 ; 1978.
 
2) 臺弘. 生活療法の復権. 精神医学 1984 ; 26 : 803-814.
 
3) 臺弘ほか (編). 続・分裂病の生活臨床. 創造出版 ; 1987.
 
4) 安西信雄ほか. 大学病院における Day Hospital-その役割と可能性. 臨床精神医学 1981 ; 10 : 285-293.
 
5) 太田敏男ほか. デイ・ホスピタルにおける治療システムと治療過程-生活臨床と治療共同体の統合の試み. 精神療法 1980 ; 6 : 354-365.
 
6) 宮内勝ほか. 治療的働きかけへの反応の仕方にもとづく精神分裂病圏患者の臨床的類型化の試み-「自己啓発型精神分裂病患者群」と「役割啓発的接近法」の提唱 (第1報). 精神医学 1987 ; 29 : 1297-1307.
 
7) 浦河べてるの家. べてるの家の「当事者研究」. 医学書院 ; 2005.
 
8) 池淵恵美. こころの回復を支える精神障害リハビリテーション. 医学書院 ; 2019.
Medical*Online
9) Fulford KW. The value of evidence and evidence of values : Bringing together values-based and evidence-based practice in policy and service development in mental health. J Eval Clin Pract 2011 ; 17 : 976-987.
PubMed
10) 夏苅郁子ほか. 「精神科担当医の診察態度」を患者・家族はどのように評価しているか-約6,000人の調査結果とそれに基づく提言. 精神経誌 2018 ; 120 : 868-886.
 
11) Velligan DI, et al. A randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia. Schizophr Res 2015 ; 165 : 175-180.
PubMed
12) 笠井清登ほか. 統合失調UPDATE-脳・生活・人生の統合的理解にもとづく "価値医学" の最前線 はじめに. 医学のあゆみ 2017 ; 261 (10) : 913-914.
 
池淵恵美. 「陰性症状」再考-統合失調症のリカバリーに向けて. 精神経誌 2015 ; 117 : 179-194.
 
長谷川寿一 (監修), 笠井清登ほか (編). 思春期学. 東京大学出版会 ; 2015.
 
P.151 掲載の参考文献
1) 楢林理一郎. 家族療法とは-序にかえて. 日本家族研究・家族療法学会 (編), 家族療法テキストブック. 金剛出版 ; 2013, pp v-viii.
 
2) 楢林理一郎. 家族療法の理論. 日本家族研究・家族療法学会 (編), 家族療法テキストブック. 金剛出版 ; 2013, pp24-27.
 
3) Andersen T. The reflecting team : Dialogue and meta-dialogue in clinical work. Fam Process 1987 ; 26 (4) : 415-428.
PubMed
4) Seikkula J, Olson ME. The open dialogue approach to acute psychosis : Its poetics and micropolitics. Fam Process 2003 ; 42 (3) : 403-418.
PubMed
5) Bateson G, et al. Toward a Theory of Schizophrenia. Behavior Sci 1956 ; 1 (4) : 251-264.
 
6) Brown GW, et al. Post hospital adjustment of chronic mental patients. Lancet 1958 ; 272 (7048) : 685-689.
 
7) Vaughn CE, Leff JP. The influence of family and social factors on the course of psychiatric illness. A comparison of schizophrenic and depressed neurotic patients. Br J Psychiatry 1976 ; 129 : 125-137.
PubMed
8) Okpokoro U, et al. Family intervention (brief) for schizophrenia (Review). Cochrane Database of Syst Rev 2014 ; 3 : CD009802.
PubMed
9) 厚生労働省. 精神・神経疾患研究委託費13指2統合失調症の治療およびリハビリテーションのガイドライン作成とその実証的研究」研究班 (主任研究者 : 浦田重治郎). 心理教育を中心とした心理社会的援助プログラムガイドライン. 2004.
 
10) 市橋香代. 患者や家族へのわかりやすい心理教育. 笠井清登ほか (編), 精神科研修ノート改訂第2版. 診断と治療社 ; 2016, pp271-272.
 
11) 蔭山正子ほか. 精神障がいの家族ピア教育プログラムの普及-「家族による家族学習会」のケーススタディ. 日本公衛誌 2014 ; 61 : 221-232.
 
12) The Meriden Family Programme. Family Work ; 2019. https://www.meridenfamilyprogramme.com
 
Andersen, T. The Reflecting Team : Dialogues and Dialogues About the Dialogues. New York : W. W. Norton & Company ; 1991/鈴木浩二 (監訳). リフレクティング・プロセス-会話における会話と会話. 金剛出版 ; 2001.
 
Bateson G. Steps to an Ecology of Mind. Chigago : The University of Chicago Press ; 2000/佐藤良明 (訳). 精神の生態学, 改訂第2版. 新思索社 ; 2000.
 
鈴木丈, 伊藤順一郎. SSTと心理教育. 中央法規出版 ; 1997.
 
斎藤環 (著+訳). オープンダイアローグとは何か. 医学書院 ; 2015.
 
P.156 掲載の参考文献
1) Tiihonen J, et al. No mental health without physical health. Lancet 2011 ; 377 (9766) : 611.
PubMed
2) Kraepelin E. Psychiatrie : Ein Lehrbuch fur Studierende und Arzte. Leipzig : Verlag von Johann Ambrosius Barth ; 1913/西丸四方, 西丸甫夫 (訳). 精神医学 第8版 I. 精神分裂病. みすず書房 ; 1986.
 
3) Huber G. Psychiatrie : Systematischer Lehrtext fur Studenten und Arzte. Stuttgart : Schattauer Verlag GmbH ; 1981/林拓二 (訳). 精神病とは何か-臨床精神医学の基本構造. 新曜社 ; 2005.
 
4) Chang HA, et al. Cardiac autonomic dysregulation in acute schizophrenia. Acta Neuropsychiatr 2013 ; 25 (3) : 155-164.
PubMed
5) Herbsleb M, et al. Chronotropic incompetence of the heart is associated with exercise intolerance in patients with schizophrenia. Schizophr Res 2018 ; 197 : 162-169.
PubMed
6) Firth J, et al. The Lancet Psychiatry Commission : A blueprint for protecting physical health in people with mental illness. Lancet Psychiatry 2019 ; 6 : 675-712.
PubMed
7) Correll CU, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness : A large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 2017 ; 16 : 163-180.
PubMed
8) Stubbs B, et al. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia : A systematic review and comparative meta-analysis. Acta Psychiatr Scand 2015 ; 132 : 144-157.
PubMed
9) Vancampfort D, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder : A systematic review and meta-analysis. World Psychiatry 2015 ; 14 : 339-347.
PubMed
10) 稲村雪子ほか. わが国の精神科病院における統合失調症入院患者の肥満と低体重に関する調査. 精神経誌 2013 ; 115 (1) : 10-21.
 
11) Laursen TM, et al. Excess early mortality in schizophrenia. Annu Rev Clin Psychol 2014 ; 10 : 425-448.
PubMed
12) Kondo S, et al. Premature deaths among individuals with severe mental illness after discharge from long-term hospitalisation in Japan : A naturalistic observation during a 24-year period. BJPsych Open 2017 ; 3 : 193-195.
PubMed
13) Vancampfort D, et al. An impaired health related muscular fitness contributes to a reduced walking capacity in patients with schizophrenia : A cross-sectional study. BMC Psychiatry 2013 ; 13 : 5.
PubMed
14) Torniainen M, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull 2015 ; 41 (3) : 656-663.
PubMed
15) Moore S, et al. Promoting physical health for people with schizophrenia by reducing disparities in medical and dental care. Acta Psychiatr Scand 2015 ; 132 : 109-121.
PubMed
16) Kisely S, et al. Treatment of ischaemic heart disease and stroke in individuals with psychosis under universal healthcare. Br J Psychiatry 2009 ; 195 : 545-550.
PubMed
17) Liu NH, et al. Excess mortality in persons with severe mental disorders : A multilevel intervention frame-work and priorities for clinical practice, policy and research agendas. World Psychiatry 2017 ; 16 : 30-40.
 
18) Thornicroft G. Physical health disparities and mental illness : The scandal of premature mortality. Br J Psychiatry 2011 ; 199 : 441-442.
PubMed
19) American Diabetes Association. 1. Promoting Health and Reducing Disparities in Populations. Diabetes Care 2017 ; 40 (Suppl. 1) : S6-S10.
PubMed
20) Howell S, et al. Cardiovascular effects of psychotic illnesses and antipsychotic therapy. Heart 2019 ; 105 (24) : 1852-1859.
PubMed
P.163 掲載の参考文献
1) Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014 ; 511 (7510) : 421-427.
 
2) Sekar A, et al. Schizophrenia risk from complex variation of complement component 4. Nature 2016 ; 530 (7589) : 177-183.
PubMed
3) Takata A, et al. Loss-of-function variants in schizophrenia risk and SETD1A as a candidate susceptibility gene. Neuron 2014 ; 82 (4) : 773-780.
PubMed
4) Paylor R, Lindsay E. Mouse models of 22q11 deletion syndrome. Biol Psychiatry 2006 ; 59 (12) : 1172-1179.
PubMed
5) St. Clair D, Johnstone M. Using mouse transgenic and human stem cell technologies to model genetic mutations associated with schizophrenia and autism. Philos Trans R Soc Lond Biol Sci 2018 ; 373 (1742) : 20170037.
PubMed
6) Radua J, et al. What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry 2018 ; 17 (1) : 49-66.
PubMed
7) Meyer U. Prenatal poly (i : C) exposure and other developmental immune activation models in rodent systems. Biological Psychiatry 2014 ; 75 (4) : 307-315.
PubMed
8) Lederbogen F, et al. City living and urban upbringing affect neural social stress processing in humans. Nature 2011 ; 474 (7352) : 498-501.
 
9) Varese F, et al. Childhood Adversities Increase the Risk of Psychosis : A Meta-analysis of Patient-Control, Prospective- and Cross-sectional Cohort Studies. Schizophr Bull 2012 ; 38 (4) : 661-671.
PubMed
10) Howes OD, Kapur S. The dopamine hypothesis of schizophrenia : version III--the final common pathway. Schizophr Bull 2009 ; 35 (3) : 549-562.
PubMed
11) Kellendonk C, et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006 ; 49 (4) : 603-615.
PubMed
12) Niwa M, et al. Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits. Neuron 2010 ; 65 (4) : 480-489.
PubMed
13) Kim IH, et al. Spine pruning drives antipsychotic-sensitive locomotion via circuit control of striatal dopamine. Nat Neurosci 2015 ; 18 (6) : 883-891.
PubMed
14) Naatanen R, et al. Early selective-attention effect on evoked potential reinterpreted. Acta Psychol (Amst) 1978 ; 42 (4) : 313-329.
PubMed
15) Hamm JP, Yuste R. Somatostatin Interneurons Control a Key Component of Mismatch Negativity in Mouse Visual Cortex. Cell Rep 2016 ; 16 (3) : 597-604.
PubMed
16) Winton-Brown TT, et al. Dopaminergic basis of salience dysregulation in psychosis. Trends Neurosci 2014 ; 37 (2) : 85-94.
PubMed
17) Howes OD, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012 ; 69 (8) : 776-786.
PubMed
18) Nour MM, et al. Dopaminergic basis for signaling belief updates, but not surprise, and the link to paranoia. Proc Natl Acad Sci U S A 2018 ; 115 (43) : E10167-E10176.
 
19) Iino Y, et al. Dopamine D2 receptors in discrimination learning and spine enlargement. Nature 2020 ; 579 (7800) : 555-560.
PubMed
20) Monteggia LM, et al. Depression : The best way forward. Nature 2014 ; 515 (7526) : 200-201.
PubMed
21) LeDoux J, Daw ND. Surviving threats : Neural circuit and computational implications of a new taxonomy of defensive behaviour. Nat Rev Neurosci 2018 ; 19 (5) : 269-282.
 
22) Caspi A, et al. Role of genotype in the cycle of violence in maltreated children. Science 2002 ; 297 (5582) : 851-854.
PubMed
23) McOmish CE, et al. Identifying novel interventional strategies for psychiatric disorders : Integrating genomics, 'enviromics' and gene-environment interactions in valid preclinical models. Br J Pharmacol 2014 ; 171 (20) : 4719-4728.
PubMed
24) Freund J, et al. Emergence of individuality in genetically identical mice. Science 2013 ; 340 (6133) : 756-759.
PubMed
25) Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 ; 100 (1) : 57-70.
PubMed
Canetta S, Kellendonk C. Can we use mice to study schizophrenia? Philos Trans R Soc Lond B Biol Sci 2018 ; 373 (1742).
PubMed
LeDoux J, Daw ND. Surviving threats : Neural circuit and computational implications of a new taxonomy of defensive behaviour. Nat Rev Neurosci 2018 ; 19 (5) : 269-282.
 
Sterzer P, et al. The Predictive Coding Account of Psychosis. Biol Psychiatry 2018 ; 84 (9) : 634-643.
PubMed
Monteggia LM, et al. Depression : The best way forward. Nature 2014 ; 515 (7526) : 200-201.
PubMed
Nishioka M, et al. Somatic mutations in the human brain : Implications for psychiatric research. Mol Psychiatry 2019 ; 24 (6) : 839-856.
PubMed
Obi-Nagata K, et al. Synaptic functions and their disruption in schizophrenia : From clinical evidence to synaptic optogenetics in an animal model. Proc Jpn Acad Ser B Phys Biol Sci 2019 ; 95 (5) : 179-197.
 
P.173 掲載の参考文献
1) Murphy KC. Schizophrenia and velo-cardio-facial syndrome. Lancet 2002 ; 359 : 426-430.
PubMed
2) Kobrynski L, Sullivan KE. Velocardiofacial syndrome, DiGeorge syndrome : The chromosome 22q11.2 deletion syndromes. Lancet 2007 ; 370 : 1443-1452.
PubMed
3) Bassett AS, et al. Practical guidelines for managing patients with 22q11.2 deletion syndrome. J Pediatr 2011 ; 159 : 332-339.
PubMed
4) Donna M McDonald-McGinn, et al. 22q11.2 Deletion Syndrome. initial Posting : 1999 ; Last Update : February 28, 2013/末國久美子ほか (訳). Gene Reviews 日本語版 : 22q11.2 欠失症候群. 2012. http://grj.umin.jp/
 
5) Fung WL, et al. Practical guidelines for managing adults with 22q11.2 deletion syndrome. Genet Med 2015 ; 17 : 599-609.
PubMed
6) 石塚佳奈子, 尾崎紀夫. 22q11.2 欠失症候群. 新領域別症候群シリーズ 37 精神医学症候群 (第2版) I-発達障害・統合失調症・双極性障害・抑うつ障害. 別冊 日本臨牀 2017 ; 357-362.
 
7) 田宗秀隆ほか. 22q11.2欠失症候群-精神・身体・知的の3障害の統合的支援. 医学のあゆみ 2017 ; 261 : 981-987.
Medical*Online
8) McDonald-McGinn DM. 22q11.2 deletion syndrome : A tiny piece leading to a big picture. Am J Med Genet A 2018 ; 176 : 2055-2057.
PubMed
9) Zinkstok JR, et al. Neurobiological perspective of 22q11.2 deletion syndrome. Lancet Psychiatry 2019 ; 6 : 951-960.
PubMed
10) Marshall CR, et al. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nat Genet 2017 ; 49 : 27-35.
PubMed
11) Van L, et al. Update on the 22q11.2 deletion syndrome and its relevance to schizophrenia. Curr Opin Psychiatry 2017 ; 30 : 191-196.
PubMed
12) Kushima I, et al. Comparative Analyses of Copy-number Variation in Autism Spectrum Disorder and Schizophrenia Reveal Etiological Overlap and Biological Insights. Cell Rep 2018 ; 24 : 2838-2856.
PubMed
13) McDonald-McGinn DM, et al. 22q11.2 deletion syndrome. Nat Rev Dis Primers 2015 ; 1 : 15071.
PubMed
14) Morrow BE, et al. Molecular genetics of 22q11.2 deletion syndrome. Am J Med Genet A 2018 ; 176 : 2070-2081.
PubMed
15) Hiroi N, et al. Copy number variation at 22q11.2 : From rare variants to common mechanisms of developmental neuropsychiatric disorders. Mol Psychiatry 2013 ; 18 : 1153-1165.
PubMed
16) Yagi H, et al. Role of TBX1 in human del22q11.2 syndrome. Lancet 2003 ; 362 : 1366-1373.
PubMed
17) Campbell IM, et al. What is new with 22q? An update from the 22q and You Center at the Children's Hospital of Philadelphia. Am J Med Genet A 2018 ; 176 : 2058-2069.
 
18) Zhao Y, et al. Variance of IQ is partially dependent on deletion type among 1,427 22q11.2 deletion syndrome subjects. Am J Med Genet A 2018 ; 176 : 2172-2181.
PubMed
19) Palmer LD, et al. Elucidating the diagnostic odyssey of 22q11.2 deletion syndrome. Am J Med Genet A 2018 ; 176 : 936-944.
PubMed
20) 田宗秀隆ほか. 先天奇形および神経発達障害を有しつつも, 成人後に幻聴が出現するまで未診断で経過した22q11.2欠失症候群の1例. 精神経誌 2017 ; 119 (1) : 9-16.
 
21) Farrelly LA, et al. Histone serotonylation is a permissive modification that enhances TFIID binding to H3K4me3. Nature 2019 ; 567 : 535-539.
PubMed
22) 和田明ほか. 22q11.2欠失症候群の精神症状. Medical Practice 2019 ; 36 (11) : 1716-1718.
Medical*Online
23) Chun S, et al. Specific disruption of thalamic inputs to the auditory cortex in schizophrenia models. Science 2014 ; 344 : 1178-82.
 
24) Fernandez A, et al. Mitochondrial Dysfunction Leads to Cortical Under-Connectivity and Cognitive Impairment. Neuron 2019 ; 102 : 1127-1142.
PubMed
25) Hiroi N. Critical reappraisal of mechanistic links of copy number variants to dimensional constructs of neuropsychiatric disorders in mouse models. Psychiatry Clin Neurosci 2018 ; 72 : 301-321.
PubMed
26) Hamm JP, et al. Altered Cortical Ensembles in Mouse Models of Schizophrenia. Neuron 2017 ; 94 : 153-167.
PubMed
27) Toyoshima M, et al. Analysis of induced pluripotent stem cells carrying 22q11.2 deletion. Transl Psychiatry 2016 ; 6 : e934.
PubMed
28) Bundo M, et al. Increased L1 retrotransposition in the neuronal genome in schizophrenia. Neuron 2014 ; 81 : 306-313.
PubMed
29) van Duin EDA, et al. Lower [18F] fallypride binding to dopamine D2/3 receptors in frontal brain areas in adults with 22q11.2 deletion syndrome : A positron emission tomography study. Psychol Med 2020 ; 50 (5) : 799-807.
PubMed
30) Mancini V, et al. Positive psychotic symptoms are associated with divergent developmental trajectories of hippocampal volume during late adolescence in patients with 22q11DS. Mol Psychiatry 2019, in press. [PMID : 31164700]
 
31) Mok KY, et al. Deletions at 22q11.2 in idiopathic Parkinson's disease : A combined analysis of genomewide association data. Lancet Neurol 2016 ; 15 : 585-596.
 
32) Hiroi N, Yamauchi T. Modeling and Predicting Developmental Trajectories of Neuropsychiatric Dimensions Associated With Copy Number Variations. Int J Neuropsychopharmacol 2019 ; 22 : 488-500.
PubMed
33) 廣井昇, 吉川武男. 22q11.2欠失症候群および22q11.2重複症候群. (Last update : 2016年11月) 脳科学辞典 https://bsd.neuroinf.jp/
 
34) Meng Q, et al. The DGCR5 long noncoding RNA may regulate expression of several schizophreniarelated genes. Sci Transl Med 2018 ; 10. online available. [PMID : 30545965]
 
35) Brandon NJ, Sawa A. Linking neurodevelopmental and synaptic theories of mental illness through DISC1. Nat Rev Neurosci 2011 ; 12 : 707-722.
PubMed
36) Sumitomo A, et al. A mouse model of 22q11.2 deletions : Molecular and behavioral signatures of Parkinson's disease and schizophrenia. Sci Adv 2018 ; 4 : eaar6637.
PubMed
37) Lloyd K, White J. Democratizing clinical research. Nature 2011 ; 474 : 277-278.
PubMed
38) Tang SX, Gur RE. Longitudinal perspectives on the psychosis spectrum in 22q11.2 deletion syndrome. Am J Med Genet A 2018 ; 176 : 2192-2202.
PubMed
39) 熊倉陽介ほか. AYA世代をむかえた医療的ケア児とその家族に対する統合的支援-身体・知的・精神の重複障害をもつ22q11.2欠失症候群メンタルヘルス専門外来の立ち上げの経験から. 賃金と社会保障 2019 ; 1721 : 12-31.
 
22q-pedia. https://22q-pedia.net/
 
難病情報センター. 22q11.2欠失症候群 (指定難病 203). http://www.nanbyou.or.jp/entry/5318
 
大澤真木子, 中西敏雄 (監修). 22q11.2欠失症候群ガイドブック. 中山書店 ; 2010.
 
22q11.2欠失症候群-22q11.2欠失症候群の子どもとその親のために. http://22hc.com/file/22hc_pamphlet.pdf
 
こころの健康図鑑. http://kokoro-zukan.com/
 

3章 ライフステージに沿った統合失調症の理解と支援

P.186 掲載の参考文献
1) Lieberman JA. Neurobiology and the natural history of schizophrenia. J Clin Psychiatry 2006 ; 67 (10) : e14.
PubMed
2) Lieberman JA, et al. Science and recovery in schizophrenia. Psychiatr Serv 2008 ; 59 (5) : 487-496.
PubMed
3) Gutierrez-Galve L, et al. Changes in the frontotemporal cortex and cognitive correlates in first-episode psychosis. Biol Psychiatry 2010 ; 68 (1) : 51-60.
PubMed
4) Arango C, et al. Progressive brain changes in children and adolescents with first-episode psychosis. Arch Gen Psychiatry 2012 ; 69 (1) : 16-26.
PubMed
5) Satterthwaite TD, et al. Structural Brain Abnormalities in Youth With Psychosis Spectrum Symptoms. JAMA Psychiatry 2016 ; 73 (5) : 515-524.
PubMed
6) Reichenberg A, et al. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia : A 30-year study. Am J Psychiatry 2010 ; 167 (2) : 160-169.
PubMed
7) Laurens KR, et al. Common or distinct pathways to psychosis? A systematic review of evidence from prospective studies for developmental risk factors and antecedents of the schizophrenia spectrum disorders and affective psychoses. BMC Psychiatry 2015 ; 15 : 205.
 
8) Laurens KR, Cullen AE. Toward earlier identification and preventative intervention in schizophrenia : Evidence from the London Child Health and Development Study. Soc Psychiatry Psychiatr Epidemiol 2016 ; 51 (4) : 475-491.
PubMed
9) Schultze-Lutter F, et al. The near Babylonian speech confusion in early detection of psychosis. Schizophr Bull 2011 ; 37 (4) : 653-655.
PubMed
10) Fusar-Poli P, et al. The psychosis high-risk state : A comprehensive state-of-the-art review. JAMA Psychiatry 2013 ; 70 (1) : 107-120.
 
11) Fusar-Poli P, et al. Predicting psychosis : Meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 2012 ; 69 (3) : 220-229.
PubMed
12) Kelleher I, et al. Psychotic symptoms and population risk for suicide attempt : A prospective cohort study. JAMA Psychiatry 2013 ; 70 (9) : 940-948.
PubMed
13) 松岡洋夫. DSM-5の減弱精神病症候群をめぐって-新たな早期介入の視点. 予防精神医学 2016 ; 1 (1) : 4-16.
 
14) Yung AR, et al. Prediction of psychosis : A step towards indicated prevention of schizophrenia. Br J Psychiatry 1998 ; 172 (Suppl 33) : 14-20.
 
15) Andreasen NC, et al. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia : A prospective longitudinal MRI study. Am J Psychiatry 2013 ; 170 (6) : 609-615.
PubMed
16) Robinson D, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999 ; 56 (3) : 241-247.
PubMed
17) Valenstein M, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002 ; 40 (8) : 630-639.
PubMed
18) Guo X, et al. Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia : A randomized, 1-year study. Arch Gen Psychiatry 2010 ; 67 (9) : 895-904.
PubMed
19) Schennach R, et al. Predictors of relapse in the year after hospital discharge among patients with schizophrenia. Psychiatr Serv 2012 ; 63 (1) : 87-90.
PubMed
20) Thornicroft G, et al. Clinical outcomes of Joint Crisis Plans to reduce compulsory treatment for people with psychosis : A randomised controlled trial. Lancet 2013 ; 381 (9878) : 1634-1641.
PubMed
21) Loch AA. Schizophrenia, Not a Psychotic Disorder : Bleuler Revisited. Front Psychiatry 2019 ; 10 : 328.
 
22) Leff J, et al. The International Pilot Study of Schizophrenia : Five-year follow-up findings. Psychol Med 1992 ; 22 : 131-145.
PubMed
23) Jablensky A, et al. Schizophrenia : Manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl 1992 ; 20 : 1-97.
PubMed
24) Harrison G, et al. Recovery from psychotic illness : A 15- and 25-year international follow-up study. Br J Psychiatry 2001 ; 178 : 506-517.
PubMed
25) Jablensky A, Sartorius N. What Did the WHO Studies Really Find? Schizophr Bull 2008 ; 34 : 253-255.
PubMed
26) Hegarty JD, et al. One hundred years of schizophrenia : A meta-analysis of the outcome literature. Am J Psychiatry 1994 ; 151 : 1409-1416.
PubMed
27) Menezes NM, et al. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med 2006 ; 36 : 1349-1362.
PubMed
28) Warner R. Recovery of Schizophrenia : Psychiatry and Political Economy. London : Routledge ; 2004.
 
29) Jaaskelainen E, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 2013 ; 39 : 1296-1306.
PubMed
30) Penttila M, et al. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia : Systematic review and meta-analysis. Br J Psychiatry 2014 ; 205 : 88-94.
PubMed
31) Hjorthoj C, et al. Years of potential life lost and life expectancy in schizophrenia : A systematic review and meta-analysis. Lancet Psychiatry 2017 ; 4 (4) : 295-301.
PubMed
32) Olfson M, et al. Premature Mortality Among Adults With Schizophrenia in the United States. JAMA Psychiatry 2015 ; 72 : 1172-1181.
PubMed
33) Hou PY, et al. Risk factors for sudden cardiac death among patients with schizophrenia. Schizophr Res 2015 ; 168 : 395-401.
PubMed
34) Saha S, et al. A systematic review of mortality in schizophrenia : Is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007 ; 64 : 1123-1131.
 
35) Castagnini A, et al. Excess mortality of acute and transient psychotic disorders : Comparison with bipolar affective disorder and schizophrenia. Acta Psychiatr Scand 2013 ; 128 : 370-375.
PubMed
36) Tiihonen J, et al. 11-year follow-up of mortality in patients with schizophrenia : A population-based cohort study (FIN11 study). Lancet 2009 ; 374 : 620-627.
PubMed
37) 日本精神科病院協会. 精神障害者社会復帰サービスニーズ等調査事業報告書. 日本精神科病院協会 ; 2003.
 
38) Ucok A, et al. Employment and its relationship with functionality and quality of life inpatients with schizophrenia : EGOFORS Study. Eur Psychiatry 2012 ; 27 : 422-425.
 
39) Karagianis J, et al. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO) : Baseline characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract 2009 ; 63 : 1578-1588.
PubMed
40) Rosenheck R, et al. Barriers to employment for people with schizophrenia. Am J Psychiatry 2006 ; 163 : 411-417.
PubMed
P.192 掲載の参考文献
1) Patel V, et al. The Lancet Commission on global mental health and sustainable development. Lancet 2018 ; 392 (10157) : 1553-1598.
PubMed
2) Sawyer SM, et al. The age of adolescence. Lancet Child Adolesc Heal 2018 ; 2 (3) : 223-228.
 
3) Paus T, et al. Why do many Psychiatric disorders emerge during adolescence? Nat Rev Neurosci 2008 ; 9 (12) : 947-957.
PubMed
4) Gore FM, et al. Global burden of disease in young people aged 10-24 years : A systematic analysis. Lancet 2011 ; 377 (9783) : 2093-2102.
 
5) Patton GC, et al. Our future : A Lancet commission on adolescent health and wellbeing. Lancet 2016 ; 387 (10036) : 2423-2478.
PubMed
6) Weare K, Nind M. Mental health promotion and problem prevention in schools : What does the evidence say? Health Promot Int 2011 ; 26 (Suppl 1) : 29-69.
 
7) 福田正人. 思春期における自我の確立とその脳基盤. 長谷川寿一 (監修), 笠井清登ほか (編), 思春期学. 東京大学出版会 ; 2015, pp159-172.
 
8) Yung AR, et al. Mapping the onset of psychosis : The Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry 2005 ; 39 (11-12) : 964-971.
 
9) NICE. Psychosis and schizophrenia in adults : Prevention and management. Clinical guideline. 2014.
 
10) Penttila M, et al. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia : Systematic review and meta-analysis. Br J Psychiatry 2014 ; 205 (2) : 88-94.
PubMed
11) Hickie IB, et al. Clinical classification in mental health at the cross-roads : Which direction next? BMC Med 2013 ; 11 : 125.
PubMed
12) Ikebuchi E. [Negative Symptoms Revisited--Toward the Recovery of Persons with Schizophrenia]. Seishin Shinkeigaku Zasshi 2015 ; 117 (3) : 179-194.
PubMed
13) Craig TKJ, et al. The Lambeth Early Onset (LEO) Team : Randomised controlled trial of the effectiveness of specialised care for early psychosis. BMJ 2004 ; 329 (7474) : 1067-1070.
 
14) McDonagh MS, et al. Treatments for Schizophrenia in Adults : A Systematic Review [Internet]. Comparative Effectiveness Reviews. no. 198, 2017.
 
15) Kasai K, et al. Strengthening community mental health services in Japan. Lancet Psychiatry 2017 ; 4 (4) : 268-270.
PubMed
16) Skre I, et al. A school intervention for mental health literacy in adolescents : Effects of a non-randomized cluster controlled trial. BMC Public Health 2013 ; 13 (1) : 873.
 
17) Ojio Y, et al. Effects of school-based mental health literacy education for secondary school students to be delivered by school teachers : A preliminary study. Psychiatry Clin Neurosci 2015 ; 69 (9) : 572-579.
PubMed
18) Kutcher S, et al. A school mental health literacy curriculum resource training approach : Effects on Tanzanian teachers' mental health knowledge, stigma and help-seeking efficacy. Int J Ment Health Syst 2016 ; 10 (1) : 1-9.
 
19) 文部科学省. 児童生徒の問題行動等生徒指導上の諸問題に関する調査 (平成28年度速報値). 2016.
 
20) 文部科学省. 平成29年度児童生徒の問題行動・不登校等生徒指導上の諸課題に関する調査結果について. 2018.
 
21) 文部科学省. 高等学校学習指導要領「生きる力」2018. http://www.mext.go.jp/a_menu/shotou/new-cs/1407074.htm
 
22) 金田渉, 小池進介. 学校精神保健・予防. 笠井清登ほか (編), 統合失調症UPDATE-脳・生活・人生の統合的理解にもとづく "価値医学" の最前線 (別冊・医学のあゆみ). 医歯薬出版 ; 2017, pp17474-17479.
 
23) 中根允文, 吉岡久美子. 学校教育と正しい知識の普及啓発について. 精神医学 2013 ; 55 (11) : 1047-1052.
 
24) Kasai K. Toward an interdisciplinary science of adolescence : Insights from schizophrenia research. Neurosci Res 2013 ; 75 (2) : 89-93.
PubMed
25) Blakemore SJ. Adolescence and mental health. Lancet 2019 ; 393 (10185) : 2030-2031.
PubMed
26) Sawyer SM, et al. Adolescence : A foundation for future health. Lancet 2012 ; 379 (9826) : 1630-1640.
PubMed
27) 安藤俊太郎ほか. 思春期の精神疾患のために一般精神科医ができることは? 精神科 2016 ; 28 (4) : 338-342.
 
28) Wei Y, et al. Mental health literacy measures evaluating knowledge, attitudes and help-seeking : A scoping review. BMC Psychiatry 2015 ; 15 (1) : 291.
 
29) Wasserman D, et al. School-based suicide prevention programmes : The SEYLE cluster-randomised, controlled trial. Lancet 2015 ; 385 (9977) : 1536-1544.
PubMed
30) Yamasaki S, et al. The recognition of mental illness, schizophrenia identification, and help-seeking from friends in late adolescence. PLoS One 2016 ; 11 (3) : 1-8.
PubMed
31) 小池進介ほか. 精神疾患への早期支援, 偏見軽減を目的とした学校現場での啓発・支援活動. 精神科治療学 2016 ; 31 (増刊) : 355-360.
 
32) Koike S, et al. Long-term effect of a name change for schizophrenia on reducing stigma. Soc Psychiatry Psychiatr Epidemiol 2015 ; 50 (10) : 1519-1526.
PubMed
33) Clement S, et al. Messages to use in population-level campaigns to reduce mental health-related stigma : Consensus development study. Epidemiol Psichiatr Soc 2010 ; 19 (1) : 7-79.
 
34) 文部科学省課題解決型高度医療人材養成プログラム「職域・地域架橋型-価値に基づく支援者育成」 (2018-2022年). https://co-production-training.net/materials/
 
35) Slade M. 100 ways to support recovery : A guide for mental health professionals, 2nd ed. 2013.
 
36) Slade M. 本人のリカバリーの100の支え方-精神保健従事者のためのガイド, 第2版. 2017. http://plaza.umin.ac.jp/heart/pdf/160927.pdf
 
37) Macpherson R, et al. The relationship between clinical and recovery dimensions of outcome in mental health. Schizophr Res 2016 ; 175 (1-3) : 142-147.
 
38) Kasai K, Fukuda M. Science of recovery in schizophrenia research : Brain and psychological substrates of personalized value. NJP Schizophr 2017 ; 3 (1) : 14.
 
39) Leamy M, et al. Conceptual framework for personal recovery in mental health : Systematic review and narrative synthesis. Br J Psychiatry 2011 ; 199 (6) : 445-452.
PubMed
40) McGorry P, et al. Creating headspace for integrated youth mental health care. World Psychiatry 2019 ; 18 (2) : 140-141.
PubMed
41) 笠井清登. 総合人間科学としての思春期学. 長谷川寿一 (監修), 笠井清登ほか (編), 思春期学. 東京大学出版会 ; 2015, pp1-17.
 
P.200 掲載の参考文献
1) 長谷川寿一 (監修), 笠井清登ほか (編). 思春期学. 東京大学出版会 ; 2015.
 
2) Sawyer SM, et al. The age of adolescence. Lancet Child Adolesc Health 2018 ; 2 : 223-228.
PubMed
3) Kessler RC, et al. Age of onset of mental disorders : A review of recent literature. Curr Opin Psychiatry 2007 ; 20 : 359-364.
PubMed
4) Paus T, et al. Why do many psychiatric disorders emerge during adolescence? Nat Rev Neurosci 2008 ; 9 : 947-957.
PubMed
5) 笠井清登. 統合失調症-脳と生活と思春期発達の交点. 日本統合失調症学会 (監修), 福田正人ほか (編), 統合失調症. 医学書院 ; 2013, pp54-58.
 
6) Fusar-Poli P, et al. Predicting psychosis : Meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 2012 ; 69 : 220-229.
PubMed
7) Kelleher I, et al. Clinicopathological significance of psychotic experiences in non-psychotic young people : Evidence from four population-based studies. Br J Psychiatry 2012 ; 201 : 26-32.
PubMed
8) 中井久夫. 中井久夫コレクション 3. 「思春期を考える」ことについて. 筑摩書房 ; 2011.
 
9) van Os J, Guloksuz S. A critique of the "ultra-high risk" and "transition" paradigm. World Psychiatry 2017 ; 16 : 200-206.
 
10) Blakemore SJ. Adolescence and mental health. Lancet 2019 ; 393 (10185) : 2030-2031.
PubMed
11) 三田誠広. 十七歳で考えたこと. 河出書房新社 ; 1996, pp8-9.
 
12) 内閣府. 令和元年版 子供・若者白書. 第4章 子供・若者の成長のための社会環境の整備. https://www8.cao.go.jp/youth/whitepaper/r01honpen/pdf_index.html
 
13) プルスアルハ. 子どもの気持ちを知る絵本 (1) わたしのココロはわたしのもの-不登校って言わないで. ゆまに書房 ; 2014.
 
14) 小池進介ほか. 精神疾患への早期支援, 偏見軽減を目的とした学校現場での啓発・支援活動. 精神科治療学 2016 ; 31 (増刊号) : 355-360.
 
15) 宮田雄吾. 子どもの心の処方箋-精神科児童思春期外来の現場から. 新潮社 ; 2009.
 
16) 滝川一廣. 子どものための精神医学. 医学書院 ; 2017, pp264-267.
 
17) 内閣府. 平成30年度青少年のインターネット利用環境実態調査. https://www8.cao.go.jp/youth/youth-harm/chousa/net-jittai_list.html
 
18) Bhugra D, et al. The WPA-Lancet Psychiatry Commission on the Future of Psychiatry. Lancet Psychiatry 2017 ; 4 : 775-818.
PubMed
P.206 掲載の参考文献
1) Jaaskelainen E, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 2013 ; 39 : 1296-1306.
PubMed
2) 初瀬記史. 精神障害者の生活状況や医療ニーズについての報告-大規模な地域家族会参加者への自記式アンケート調査から. 日社精医誌 2016 ; 25 : 8-18.
 
3) 池淵恵美. 統合失調症の人の恋愛・結婚・子育ての支援. 精神科治療学 2006 ; 21 : 95-104.
 
4) Robinson GE. Treatment of schizophrenia in pregnancy and postpartum. J Popul Ther Clin Pharmacol 2012 ; 19 : e380-e386.
 
5) Miller LJ. Sexuality, reproduction, and family planning in women with schizophrenia. Schizophr Bull 1997 ; 23 : 623-635.
PubMed
6) 池淵恵美. 統合失調症の人の恋愛・結婚・子育て-症例を通しての考察. 作業療法ジャーナル 2010 ; 44 : 572-578.
 
7) Seeman MV. Clinical interventions for women with schizophrenia : Pregnancy. Acta Psychiatr Scand 2013 ; 127 : 12-22.
PubMed
8) Tienari P, Wynne LC, et al. Genotype-environment interaction in schizophrenia-spectrum disorder : Long-term follow-up study of Finnish adoptees. Br J Psychiatry 2004 ; 184 : 216-222.
PubMed
9) Higgins J, Gore R, et al. Effects of child-rearing by schizophrenic mothers : A 25-year follow-up. Acta Psychiatr Scand 1997 ; 96 : 402-404.
PubMed
池淵恵美. こころの回復を支える 精神障害リハビリテーション. 医学書院 ; 2019.
Medical*Online
P.214 掲載の参考文献
1) 池淵恵美. わが国における就労支援モデルの構築. 精神科臨床サービス 2012 ; 12 : 436-448.
 
2) 山崎修道, 浅井久枝. 精神科デイケア. 精神科臨床サービス 2009 ; 9 : 248-252.
 
3) 管心, 古川俊一. 精神科リハビリテーション. 糸川昌成 (監修), メンタル医療-原因解明と診断, 治療の最前線. シーエムシー出版 ; 2013, pp215-221.
 
4) 藤枝由美子ほか. 精神科リハビリテーションの変遷と現状-東大デイホスピタルの実践. 総合リハビリテーション 2016 ; 44 (11) : 957-962.
 
5) 石橋綾, 管心. 統合失調症を持つ当事者への就労支援. 医学の歩み 2017 ; 261 (10) : 1043-1049.
 
6) 相澤欽一. 現場で使える精神障害者雇用支援ハンドブック. 金剛出版 ; 2007.
 
7) McGurk SR, et al. Cognitive Enhancement Treatment for People With Mental Illness Who Do Not Respond to Supported Employment : A Randomized Controlled Trial. Am J Psychiatry 2015 ; 172 (9) : 852-861.
 
8) 管心. 成人に対する精神保健福祉サービス. 下山晴彦ほか (編), 公認心理師必携 精神医療・臨床心理の知識と技法. 医学書院 ; 2016, pp149-151.
 
P.221 掲載の参考文献
1) American Psychiatric Association. Diagnostic Statistical Manual of Mental Disorders : DSM-5. American Psychiatric Publisher ; 2013.
 
2) Shinagawa S, et al. Psychosis in frontotemporal dementia. J Alzheimers Dis 2014 ; 42 : 485-499.
PubMed
3) Hall D, Finger EC. Psychotic symptoms in frontotemporal dementia. Curr Neurol Neurosci Rep 2015 ; 15 : 46-54.
PubMed
4) 古茶大樹, 針間博彦. 病の「種」と「類型」, 「階層原則」-精神障害の分類の原則について. 臨床精神病理 2010 ; 31 : 7-17.
 
5) 古茶大樹. 臨床精神病理学-精神医学における疾患と診断. 日本評論社 ; 2019.
 
6) Insel T. The NIMH Research Domain Criteria (RDoC) Project : Precision medicine for psychiatry. Am J Psychiatry 2014 ; 171 : 395-397.
PubMed
7) Roth M. The natural history of mental disorders in old age. J Ment Sci 1955 ; 101 : 281-290.
 
8) Kay DWK, Roth M. Environmental and hereditary factors in the schizophrenia of old age ("late paraphrenia") and their bearing on the general problem of causation in schizophrenia. J Ment Sci 1961 ; 107 : 649-686.
 
9) Janzarik W. Uber das Kontaktmangelparanoid des hoheren Alters und den Syndromcharakter schizophrenen Krankseins. Nervenarzt 1973 ; 44 : 515-526.
 
10) Sommer M. Zur Kenntnis der Spatkatatonie. Zeitschr Neurol Psychiat 1910 ; 1 : 523-555.
 
11) 古茶大樹. 遅発緊張病について-自験例に基づく症状, 経過, 下位群, 治療の臨床精神病理学的検討. 精神経誌 1998 ; 100 : 24-50.
 
12) Kocha H, et al. Revisiting the concept of late catatonia. Compr Psychiatry 2014 ; 55 : 1485-1490.
PubMed
13) Kraepelin E. Melancholie. Psychiatrie. Funfte, vollstandig umgearbeitete. 5 Auflage. Leipzig : Verlag von Johann Ambrosius Barth ; 1896, pp561-585.
 
14) 古茶大樹, 古野毅彦. 退行期メランコリーについて. 精神経誌 2009 ; 111 : 373-387.
 
15) Howard R, et al. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis : An international consensus. Am J Psychiat 2000 ; 157 : 172-178.
PubMed
16) Reeves SJ, et al. Increased first-contact rates for very-late-onset schizophrenia-like psychosis in Africanand Caribbean-born elders. Br J Psychiatry 2001 ; 179 : 172-174.
PubMed
17) Howard R, et al. Antipsychotic treatment of very-late-onset schizophrenia-like psychosis (ATLAS) : A randomized, controlled, double-blind trial. Lancet Psychiatry 2018 ; 5 : 553-563.
 
18) Van Assche L, et al. The neuropsychology and neurobiology of late-onset schizophrenia and very-late-onset schizophrenia-like psychosis : A critical review. Neurosci Biobehav Rev 2017 ; 83 : 604-621.
PubMed
19) Van Assche L, et al. The Neuropsychological Profile and Phenomenology of Late-Onset Psychosis : A Cross-Sectional Study on the Differential Diagnosis of Very-Late-Onset Schizophrenia-Like Psychosis, Dementia with Lewy Bodies and Alzheimer's Type Dementia with Psychosis. Arch Clin Neuropsychol 2019 ; 34 : 183-199.
 

4章 共に創る統合失調症の理解と支援に向けた対話

P.230 掲載の参考文献
1) Frank E, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991 ; 48 (9) : 851-855.
PubMed
2) Andreasen AC, et al. Remission in Schizophrenia : Proposed Criteria and Rationale for Consensus. Am J Psychiatry 2005 ; 162 : 441-449.
 
3) Kay SR, et al. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987 ; 13 : 261-276.
PubMed
4) Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962 ; 10 : 799-812.
 
5) Lambert M, et al. Remission in schizophrenia : Validity, frequency, predictors, and patients' perspective 5 years later. Dialogues Clin Neurosci 2010 ; 12 : 393-407.
PubMed
6) Liberman RP, et al. Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiatry 2002 ; 14 : 256-272.
 
7) Robinson DG, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 2004 ; 161 (3) : 473-479.
PubMed
8) Jaaskelainen E, et al. A Systematic Review and Meta-Analysis of Recovery in Schizophrenia. Schizophr Bull 2013 ; 39 (6) : 1296-1306.
PubMed
9) Heinrichs DW, et al. The Quality of Life Scale : An instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984 ; 10 : 388-398.
PubMed
10) Kaneda Y, et al. Schizophrenia Quality of Life Scale : Validation of the Japanese version. Psychiatry Res 2002 ; 113 : 107-113.
PubMed
11) Aki H, et al. Subjective and objective quality of life, levels of life skills, and their clinical determinants in outpatients with schizophrenia. Psychiatry Res 2008 ; 158 : 19-25.
 
12) Yamauchi K, et al. Predictors of subjective and objective quality of life in outpatients with schizophrenia. Psychiatry Clin Neurosci 2008 ; 62 : 404-411.
PubMed
13) Ueoka Y, et al. Quality of life and cognitive dysfunction in people with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011 ; 35 (1) : 53-59.
PubMed
14) Kane J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988 ; 45 : 789-796.
PubMed
15) McEvoy JP, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006 ; 163 : 600-610.
 
16) Taipale H, et al. Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up. Schizophr Bull 2018 ; 44 (6) : 1381-1387.
PubMed
17) Samara MT, et al. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia, A Network Meta-analysis. JAMA Psychiatry 2016 ; 73 (3) : 199-210.
PubMed
18) Meltzer HY, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizo-phrenic patients. Hosp Community Psychiatry 1990 ; 41 : 892-897.
 
19) Olagunju AT, et al. Clozapine and Psychosocial Function in Schizophrenia : A Systematic Review and Meta-Analysis. CNS Drugs 2018 ; 32 (11) : 1011-1023.
PubMed
20) Lawrence D, et al. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia : Retrospective analysis of population based registers. BMJ 2013 ; 346 : f2539.
PubMed
21) Hjorthoj C, et al. Years of potential life lost and life expectancy in schizophrenia : A systematic review and meta-analysis. Lancet Psychiatry 2017 ; 4 (4) : 295-301.
PubMed
22) Tiihonen J, et al. 11-year follow-up of mortality in patients with schizophrenia : A population-based cohort study (FIN11 study). Lancet 2009 ; 374 : 620-627.
PubMed
23) Khan A, et al. Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials. J Clin Psychiatry 2007 ; 68 : 1828-1833.
PubMed
24) Murray-Thomas T, et al. Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users : A study with the general practice research database. Cardiovasc Psychiatry Neurol 2013 ; 2013 : 247486.
PubMed
25) The James Lind Alliance. http://www.jla.nihr.ac.uk/
 
26) Lloyd K, White J. Democratizing clinical research. Nature 2011 ; 474 (7351) : 277-278.
PubMed
27) Bipolar top 10. The James Lind Alliance. http://www.jla.nihr.ac.uk/priority-setting-partnerships/bipolar/top-10-priorities/top-10-priorities.htm
 
日本統合失調症学会 (監修), 福田正人ほか (編). 統合失調症. 医学書院 ; 2013.
 
日本神経精神薬理学会 (編). 統合失調症薬物治療ガイド-患者さん・ご家族・支援者のために. 2018. http://www.asas.or.jp/jsnp/img/csrinfo/szgl_guide.pdf
 
日本精神神経学会ほか (編). 精神疾患の克服と障害支援にむけた研究推進の提言. 2018. https://www.jspn.or.jp/uploads/uploads/files/activity/20180519.pdf
 
P.236 掲載の参考文献
1) Slade M. Wellbeing, Recovery and Mental Health. Cambridge, UK : Cambridge University Press ; 2017.
 
2) Slade M. Mental illness and well-being : The central importance of positive psychology and recovery approaches. BMC Health Serv Res 2010 ; 10 : 26.
PubMed
3) Liberman RP, et al. Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiatry 2002 ; 14 : 256-272.
 
4) Jaaskelainen E, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 2013 ; 39 (6) : 1296-1306.
PubMed
5) Slade M, et al. Recovery : An international perspective. Epidemiol Psichiatr Soc 2008 ; 17 (2) : 128-137.
PubMed
6) Anthony WA. Recovery from mental illness : The guiding vision of the mental health service system in the 1990s. Psychosocial Rehabilitation Journal 1993 ; 16 (4) : 11-23.
 
7) 村井俊哉. 精神医学の概念デバイス. 創元社 ; 2018.
 
8) Leamy M, et al. Conceptual framework for personal recovery in mental health : Systematic review and narrative synthesis. Br J Psychiatry 2011 ; 199 (6) : 445-452.
PubMed
9) Pope C, Mays N. Reaching the parts other methods cannot reach : An introduction to qualitative methods in health and health services research. BMJ 1995 ; 311 (6996) : 42-45.
PubMed
10) Braun V, Clarke V. Novel insights into patients' life-worlds : The value of qualitative research. Lancet Psychiatry 2019 ; 6 (9) : 720-721.
PubMed
11) Law H, et al. Recovery from psychosis : A user informed review of self-report instruments for measuring recovery. J Ment Health 2012 ; 21 (2) : 192-207.
 
12) Sklar M, et al. Instruments for measuring mental health recovery : A systematic review. Clin Psychol Rev 2013 ; 33 (8) : 1082-1095.
PubMed
13) Shanks V, et al. Measures of personal recovery : A systematic review. Psychiatr Serv 2013 ; 64 (10) : 974-980.
PubMed
14) Neil S, et al. The questionnaire about the process of recovery (QPR) : A measurement tool developed in collaboration with service users. Psychosis 2009 ; 1 (2) : 145-155.
 
15) Kanehara A, et al. The Japanese version of the questionnaire about the process of recovery : Development and validity and reliability testing. BMC Psychiatry 2017 ; 17 (1) : 360.
PubMed
16) Kanehara A, et al. Correction to : The Japanese version of the questionnaire about the process of recovery : development and validity and reliability testing. BMC Psychiatry 2020 ; 20 (1) : 12.
 
17) Chien WT, Chan ZC. Chinese translation and validation of the questionnaire on the process of recovery in schizophrenia and other psychotic disorders. Res Nurs Health 2013 ; 36 (4) : 400-411.
PubMed
18) Argentzell E, et al. Measuring personal recovery-psychometric properties of the Swedish Questionnaire about the Process of Recovery (QPR-Swe). Nord J Psychiatry 2017 ; 71 (7) : 529-535.
PubMed
19) Tse S, et al. Differences and similarities between functional and personal recovery in an Asian population : A cluster analytic approach. Psychiatry 2014 ; 77 (1) : 41-56.
 
20) Slade M, et al. International differences in understanding recovery : Systematic review. Epidemiol Psychiatr Sci 2012 ; 21 (4) : 353-364.
PubMed
21) Slade M, et al. Uses and abuses of recovery : Implementing recovery-oriented practices in mental health systems. World Psychiatry 2014 ; 13 (1) : 12-20.
PubMed
22) Van Eck RM, et al. The Relationship Between Clinical and Personal Recovery in Patients With Schizophrenia Spectrum Disorders : A Systematic Review and Meta-analysis. Schizophr Bull 2018 ; 44 (3) : 631-642.
PubMed
23) Macpherson R, et al. The relationship between clinical and recovery dimensions of outcome in mental health. Schizophr Res 2016 ; 175 (1-3) : 142-147.
 
24) Lim M, et al. An Asian study on clinical and psychological factors associated with personal recovery in people with psychosis. BMC Psychiatry 2019 ; 19 (1) : 256.
 
25) Kraiss JT, et al. Measuring personal recovery in people with bipolar disorder and exploring its relationship with well-being and social-role participation. Clin Psychol Psychother 2019 ; 26 (5) : 540-549.
PubMed
26) Slade M, et al. Supporting recovery in patients with psychosis through care by community-based adult mental health teams (REFOCUS) : A multisite, cluster, randomised, controlled trial. Lancet Psychiatry 2015 ; 2 (6) : 503-514.
PubMed
27) Meadows G, et al. REFOCUS-PULSAR recovery-oriented practice training in specialist mental health care : A stepped-wedge cluster randomised controlled trial. Lancet Psychiatry 2019 ; 6 (2) : 103-114.
PubMed
28) Thomas N, et al. Randomised controlled trial of a digitally assisted low intensity intervention to promote personal recovery in persisting psychosis : SMART-Therapy study protocol. BMC Psychiatry 2016 ; 16 (1) : 312.
PubMed
29) Kotake R, et al. Reliability and validity of the Japanese version of the INSPIRE measure of staff support for personal recovery in community mental health service users in Japan. BMC Psychiatry 2020 ; 20 (1) : 51.
PubMed
30) Wood L, Alsawy S. Recovery in Psychosis from a Service User Perspective : A Systematic Review and Thematic Synthesis of Current Qualitative Evidence. Community Ment Health J 2018 ; 54 (6) : 793-804.
PubMed
31) Soundy A, et al. Identifying the facilitators and processes which influence recovery in individuals with schizophrenia : A systematic review and thematic synthesis. J Ment Health 2015 ; 24 (2) : 103-110.
PubMed
32) Petersen KS, et al. Recovery from mental illness : A service user perspective on facilitators and barriers. Community Ment Health J 2015 ; 51 (1) : 1-13.
PubMed
33) Tew J, et al. Social Factors and Recovery from Mental Health Difficulties : A Review of the Evidence. Br J Soc Work 2012 ; 42 (3) : 443-460.
 
P.244 掲載の参考文献
1) Tambuyzer E, et al. Patient involvement in mental health care : One size does not fit all. Health Expect 2014 ; 17 (1) : 138-150.
 
2) 熊倉陽介ほか. こころと身体の健康はひとつながり-価値に基づく統合的支援. 笠井清登ほか (編), 統合失調症UPDATE-脳・生活・人生の統合的理解に基づく "価値医学" の最前線 (別冊・医学のあゆみ). 医歯薬出版 ; 2018, pp13-20.
 
3) Fulford KWM, et al. Essential Values-Based Practice : Clinical Stories Linking Science with People. Cambridge University Press ; 2012.
 
4) 熊倉陽介, 清野賢司. どうして住まいの支援からはじめる必要があるのか-ホームレス・ハウジングファースト・援助希求の多様性・つながりをめぐる支援論. 松本俊彦 (編), 「助けて」が言えない-SOSを出さない人に支援者は何ができるか. 日本評論社 ; 2019.
 
5) 山口創生, 熊倉陽介. 統合失調症患者における共同意思決定-新しいアプローチとシステム. 笠井清登ほか (編), 統合失調症UPDATE-脳・生活・人生の統合的理解にもとづく "価値医学" の最前線 (別冊・医学のあゆみ). 医歯薬出版 ; 2018, pp29-36.
 
6) Duncan E, et al. Shared decision making interventions for people with mental health conditions. Cochrane Database Syst Rev 2010 ; 1 : CD007297.
PubMed
7) 精神科外来での共同意思決定支援ツール「質問促進パンフレット」https://decisionaid.tokyo/
 
8) 精神科の診察における共同意思決定支援ツール「診察サプリ」https://kokoro-zukan.com/archives/421
 
9) 熊倉陽介. 質問促進パンフレットを用いたリカバリー志向の診療. 精神経誌 2016 ; 118 (10) : 757-765.
 
10) 宮本有紀, 小川亮. コ・プロダクション (共同創造) は英国の精神保健医療福祉施策にどのように位置づけられているか. 響き合う街で 2019 ; 87 : 11-16.
 
11) 熊谷晋一郎. 知の共同創造のための方法論. 熊谷晋一郎 (編), 当事者研究と専門知-生き延びるための知の再配置 (臨床心理学増刊 第10号). 金剛出版 ; 2018.
 
12) EY新日本有限責任監査法人. 臨床研究等における患者・市民参画に関する動向調査報告書. https://www.amed.go.jp/content/000049456.pdf
 
13) 日本医療研究開発機構. 患者・市民参画 (PPI) ガイドブック-患者と研究者の協働を目指す第一歩として. https://www.amed.go.jp/content/000055213.pdf
 
14) Sweeney A, et al. Hearing the voices of service user researchers in collaborative qualitative data analysis : The case for multiple coding. Health Expect 2013 ; 16 (4) : e89-e99.
PubMed
15) The James Lind Alliance. Schizophrenia Top 10. http://www.jla.nihr.ac.uk/priority-setting-partnerships/schizophrenia/top-10-priorities/
 
16) 熊谷晋一郎ほか. 言いっぱなし聞きっぱなしの「当事者研究会議」. 熊谷晋一郎 (編), 当事者研究と専門知-生き延びるための知の再配置 (臨床心理学増刊 第10号). 金剛出版 ; 2018.
 
P.249 掲載の参考文献
1) 綾屋紗月. 当事者研究が受け継ぐべき歴史と理念. 熊谷晋一郎ほか (責任編集), 当事者研究をはじめよう (臨床心理学 増刊第11号). 金剛出版 ; 2019, pp6-13.
 
2) 綾屋紗月. 当事者研究を体験しよう-ワークシートを用いた実践. 熊谷晋一郎 (責任編集), 当事者研究をはじめよう (臨床心理学 増刊第11号). 金剛出版 ; 2019, pp88-105.
 
3) 熊谷晋一郎, 國分功一郎. 来たるべき当事者研究. 熊谷晋一郎 (編), みんなの当事者研究 (臨床心理学 増刊第9号). 金剛出版 ; 2017, pp12-34.
 
4) 油田優衣. 強迫的・排他的な理想としての <強い障害者像> -介助者との関係における「私」の体験から. 熊谷晋一郎 (責任編集), 当事者研究をはじめよう (臨床心理学 増刊第11号). 金剛出版 ; 2019, pp27-40.
 
5) 上岡陽江・ゆき. ダルク女性ハウスの当事者研究-多重スティグマを超える「記憶の共有化」. 熊谷晋一郎 (責任編集), 当事者研究をはじめよう (臨床心理学 増刊第11号). 金剛出版 ; 2019, pp14-26.
 
6) 熊谷晋一郎. 知の共同創造のための方法論. 熊谷晋一郎 (責任編集), 当事者研究と専門知 (臨床心理学 増刊第10号). 金剛出版 ; 2018, pp2-6.
 
7) 松田博幸. ピアワーカーの政治 (politics). 熊谷晋一郎 (責任編集), 当事者研究と専門知 (臨床心理学 増刊第10号). 金剛出版 ; 2018, pp105-111.
 
8) 川合千那未ほか. 世代間継承 (1) -身体障害・難病編. 熊谷晋一郎 (責任編集), 当事者研究と専門知 (臨床心理学 増刊第10号). 金剛出版 ; 2018, pp39-52.
 
9) 秋元恵一郎ほか. 世代間継承 (2) -自助グループ編. 熊谷晋一郎 (責任編集), 当事者研究と専門知 (臨床心理学 増刊第10号). 金剛出版 ; 2018, pp58-63.
 
熊谷晋一郎 (編). みんなの当事者研究 (臨床心理学 増刊第9号). 金剛出版 ; 2017.
 
熊谷晋一郎 (責任編集). 当事者研究と専門知 (臨床心理学 増刊第10号). 金剛出版 ; 2018.
 
熊谷晋一郎 (責任編集). 当事者研究をはじめよう (臨床心理学 増刊第11号). 金剛出版 ; 2019.
 
P.255 掲載の参考文献
1) Simon B. Shame, stigma and mental illness in ancient Greece. In : Fink PJ, Tasman A (eds). Stigma and mental illness. Washington DC : American Psychiatric Press ; 1992, pp29-40.
 
2) 呉秀三, 樫田五郎. 精神病者私宅監置ノ実況及ビ其統計的視察. 創造出版 ; 2000.
 
3) Ando S, et al. Review of mental health-related stigma in Japan. Psychiatry Clin Neurosci 2013 ; 67 : 471-482.
PubMed
4) Link BG, Phelan JC. Conceptualizing Stigma. Annu Rev Sociol 2001 ; 27 : 363-385.
 
5) Corrigan PW, et al. Structural levels of mental illness stigma and discrimination. Schizophr Bull 2004 ; 30 : 481-491.
PubMed
6) Hatzenbuehler ML. Structural stigma and health inequalities : Research evidence and implications for psychological science. Am Psychol 2016 ; 71 : 742-751.
 
7) Corrigan PW, Watson AC. Understanding the impact of stigma on people with mental illness. World Psychiatry 2002 ; 1 : 16-20.
PubMed
8) Rusch N, et al. Mental illness stigma : Concepts, consequences, and initiatives to reduce stigma. Eur Psychiatry 2005 ; 20 : 529-539.
PubMed
9) Thornicroft G, et al. Stigma : Ignorance, prejudice or discrimination? Br J Psychiatry 2007 ; 190 : 192-193.
 
10) Ucok A, et al. Anticipated discrimination among people with schizophrenia. Acta Psychiatr Scand 2012 ; 125 : 77-83.
PubMed
11) Brohan E, et al. Experiences of mental illness stigma, prejudice and discrimination : A review of measures. BMC Health Serv Res 2010 ; 10 : 80.
PubMed
12) Angermeyer MC, Schomerus G. State of the art of population-based attitude research on mental health : A systematic review. Epidemiol Psychiatr Sci 2016 ; 6 : 252-264.
PubMed
13) Kaushik A, et al. The stigma of mental illness in children and adolescents : A systematic review. Psychiatry Res 2016 ; 243 : 469-494.
PubMed
14) Henderson C, et al. Mental health-related stigma in health care and mental health-care settings. Lancet Psychiatry 2014 ; 1 : 467-482.
PubMed
15) Yin M, et al. Experience of stigma among family members of people with severe mental illness : A qualitative systematic review. Int J Ment Health Nurs 2020 ; 29 (2) : 141-160.
PubMed
16) Crisp AH, et al. Stigmatisation of people with mental illnesses. Br J Psychiatry 2000 ; 177 : 4-7.
PubMed
17) Koike S, et al. Long-term effect of a name change for schizophrenia on reducing stigma. Soc Psychiatry Psychiatr Epidemiol 2015 ; 50 : 1519-1526.
PubMed
18) Thornicroft G, et al. Global pattern of experienced and anticipated discrimination against people with schizophrenia : A cross-sectional survey. Lancet 2009 ; 373 : 408-415.
PubMed
19) Gerlinger G, et al. Personal stigma in schizophrenia spectrum disorders : A systematic review of prevalence rates, correlates, impact and interventions. World Psychiatry 2013 ; 12 : 155-164.
PubMed
20) Brohan E, et al. Self-stigma, empowerment and perceived discrimination among people with schizophrenia in 14 European countries : The GAMIAN-Europe study. Schizophr Res 2010 ; 122 : 232-238.
PubMed
21) 山口創生ほか. 精神障害者に対するスティグマの是正への根拠-スティグマがもたらす悪影響に関する国際的な知見. 精リハ誌 2011 ; 15 : 75-85.
 
22) Thornicroft G. Shunned : Discrimination against People with Mental Illness. New York : Oxford University Press ; 2006.
 
23) Lysaker PH, et al. Toward understanding the insight paradox : Internalized stigma moderates the association between insight and social functioning, hope, and self-esteem among people with schizophrenia spectrum disorders. Schizophr Bull 2007 ; 33 : 192-199.
PubMed
24) Livingston JD, Boyd JE. Correlates and consequences of internalized stigma for people living with mental illness : A systematic review and meta-analysis. Soc Sci Med 2010 ; 71 : 2150-2161.
PubMed
25) Angermeyer M, Schomerus G. A stigma perspective on recovery. World Psychiatry 2012 ; 11 : 163-164.
PubMed
26) Coleman SJ, et al. Stigma-related barriers and facilitators to help seeking for mental health issues in the armed forces : A systematic review and thematic synthesis of qualitative literature. Psychol Med 2017 ; 47 : 1880-1892.
PubMed
27) Gulliver A, et al. Perceived barriers and facilitators to mental health help-seeking in young people : A systematic review. BMC Psychiatry 2010 ; 10 : 113.
PubMed
28) Gronholm PC, et al. Mental health-related stigma and pathways to care for people at risk of psychotic disorders or experiencing first-episode psychosis : A systematic review. Psychol Med 2017 ; 47 : 1867-1879.
PubMed
29) Haugen PT, et al. Mental health stigma and barriers to mental health care for first responders : A systematic review and meta-analysis. J Psychiatr Res 2017 ; 94 : 218-229.
PubMed
30) Schnyder N, et al. Association between mental health-related stigma and active help-seeking : Systematic review and meta-analysis. Br J Psychiatry 2017 ; 210 : 261-268.
PubMed
31) Clement S, et al. What is the impact of mental health-related stigma on help-seeking? A systematic review of quantitative and qualitative studies. Psychol Med 2015 ; 45 : 11-27.
PubMed
32) Griffiths KM, et al. Effectiveness of programs for reducing the stigma associated with mental disorders. A meta-analysis of randomized controlled trials. World Psychiatry 2014 ; 13 : 161-175.
PubMed
33) Morgan AJ, et al. Interventions to reduce stigma towards people with severe mental illness : Systematic review and meta-analysis. J Psychiatr Res 2018 ; 103 : 120-133.
PubMed
34) Janouskova M, et al. Can video interventions be used to effectively destigmatize mental illness among young people? A systematic review. Eur Psychiatry 2017 ; 41 : 1-9.
PubMed
35) Mehta N, et al. Evidence for effective interventions to reduce mental health-related stigma and discrimination in the medium and long term : Systematic review. Br J Psychiatry 2015 ; 207 : 377-384.
PubMed
36) Corrigan P, et al. Do the effects of antistigma programs persist over time? Findings from a meta-analysis. Psychiatr Serv 2015 ; 66 : 543-546.
PubMed
37) Yamaguchi S, et al. Long-term effects of filmed social contact or internet-based self-study on mental healthrelated stigma : A 2-year follow-up of a randomised controlled trial. Soc Psychiatry Psychiatr Epidemiol 2019 ; 54 : 33-42.
 
38) Reinke RR, et al. Examining two aspects of contact on the stigma of mental illness. J Soc Clin Psychol 2004 ; 23 : 377-389.
 
39) Corrigan PW, et al. The California schedule of key ingredients for contact-based antistigma programs. Psychiatr Rehabil J 2013 ; 36 : 173-179.
PubMed
40) Corrigan PW, et al. Challenging the public stigma of mental illness : A meta-analysis of outcome studies. Psychiatr Serv 2012 ; 3 : 963-973.
 
41) Chisholm K, et al. Impact of contact on adolescents' mental health literacy and stigma : The SchoolSpace cluster randomised controlled trial. BMJ Open 2016 ; 6 : e009435.
PubMed
42) Angermeyer MC, et al. Biogenetic explanations and public acceptance of mental illness : Systematic review of population studies. Br J Psychiatry 2011 ; 199 : 367-372.
PubMed
43) Ojio Y, et al. Effects of biomedical messages and expert-recommended messages on reducing mental health-related stigma : A randomised controlled trial. Epidemiol Psychiatr Sci 2019 ; 29 : e74.
PubMed
44) Clement S, et al. Messages to use in population-level campaigns to reduce mental health related stigma : Consensus development study. Epidemiol Psichiatr Soc 2010 ; 19 : 72-79.
 
45) Yamaguchi S, et al. Effects of short-term interventions to reduce mental health-related stigma in university or college students : A systematic review. J Nerv Ment Dis 2013 ; 201 : 490-503.
PubMed
46) Ando S, et al. The simulation of hallucinations to reduce the stigma of schizophrenia : A systematic review. Schizophr Res 2011 ; 133 : 8-16.
PubMed
47) Henderson C, et al. Mental illness stigma, help seeking, and public health programs. Am J Public Health 2013 ; 103 : 777-780.
PubMed
48) Henderson C, Thornicroft G. Stigma and discrimination in mental illness : Time to Change. Lancet 2009 ; 373 : 1928-1930.
PubMed
49) Gronholm PC, et al. Interventions to reduce discrimination and stigma : The state of the art. Soc Psychiatry Psychiatr Epidemiol 2017 ; 52 : 249-258.
PubMed
50) Thornicroft G, et al. Evidence for effective interventions to reduce mental-health-related stigma and discrimination. Lancet 2016 ; 387 : 1123-1132.
PubMed
51) Wood L, et al. Psychosocial interventions for internalised stigma in people with a schizophrenia-spectrum diagnosis : A systematic narrative synthesis and meta-analysis. Schizophr Res 2016 ; 176 : 291-303.
PubMed
52) Tsang HW, et al. Therapeutic intervention for internalized stigma of severe mental illness : A systematic review and meta-analysis. Schizophr Res 2016 ; 173 : 45-53.
PubMed
53) Buchter RB, Messer M. Interventions for reducing self-stigma in people with mental illnesses : A systematic review of randomized controlled trials. Ger Med Sci 2017 ; 15 : Doc07.
PubMed
54) Lasalvia A, et al. Should the label "schizophrenia" be abandoned? Schizophr Res 2015 ; 162 : 276-284.
PubMed
55) Yamaguchi S, et al. Associations between renaming schizophrenia and stigma-related outcomes : A systematic review. Psychiatry Clin Neurosci 2017 ; 71 : 347-362.
PubMed
56) Koike S, et al. Effect of name change of schizophrenia on mass media between 1985 and 2013 in Japan : A text data mining analysis. Schizophr Bull 2016 ; 42 : 552-559.
PubMed
57) Thornicroft G, Tansella M. Better Mental Health Care. Cambridge : Cambridge University Press ; 2009.
 
58) Callard F, Rose D. The mental health strategy for Europe : Why service user leadership in research is indispensable. J Ment Health 2012 ; 21 : 219-226.
PubMed
59) 山口創生. 研究におけるコ・プロダクションと当事者参画の世界潮流と日本での可能性. 響き合う街で 2019 ; 124 : 31-35.
 
P.263 掲載の参考文献
1) Perkins R, et al. Recovery Colleges. Implementing Recovery through Organisational Change (ImROC) Briefing Paper. 2012. http://www.centreformentalhealth.org.uk/pdfs/Recovery_Colleges.pdf.
 
2) Perkins R, et al. Recovery Colleges 10 Years On. Implementing Recovery through Organisational Change (ImROC) Briefing Paper. 2018. https://imroc.org/resources/15-recovery-colleges-10-years/.
 
3) リカバリーカレッジガイダンス研究班. リカバリーカレッジの理念と実践例 (リカバリーカレッジガイダンス) 2019. http://recoverycollege-research.jp/guidance/.
 
4) Thomas EC, et al. Person-Oriented Recovery of Individuals With Serious Mental Illnesses : A Review and Meta-Analysis of Longitudinal Findings. Psychiatr Serv 2018 ; 69 (3) : 259-267.
PubMed
5) 宮本有紀ほか. 主体的参加によるリカバリー促進実践-英国リカバリーカレッジの提供する講座内容の分析. 第12回日本統合失調症学会 ; 2017.
 
6) リカバリーカレッジ. 東京都三鷹市 : 社会福祉法人巣立ち会 ; 2019. http://sudachikai.eco.to/pia/
 
7) リカバリーカレッジたちかわ. 東京都立川市. http://recoverycollege.jp/tachikawa/
 
8) リカバリーカレッジ名古屋. 愛知県名古屋市 : 一般社団法人しん. https://recoverycollege-nagoya.com/
 
9) CNWL Recovery & Wellbeing College. London : Central and North West London NHS Foundation Trust ; 2019. https://www.cnwl.nhs.uk/recovery-college/
 
10) Perkins AM, et al. Impacts of attending recovery colleges on NHS staff. Mental Health and Social Inclusion 2017 ; 21 : 1-7.
 
11) Meddings S, et al. Recovery colleges : Quality and outcomes. Mental Health and Social Inclusion 2015 ; 19 (4) : 212-221.
 
12) Australian Healthcare Associates. Literature review to inform the development of Recovery Colleges in Western Australia. Melbourne ; 2018.
 
13) Bourne P, et al. An evaluation of service use outcomes in a Recovery College. J Ment Health 2018 ; 27 (4) : 359-366.
 
14) Toney R, et al. Mechanisms of Action and Outcomes for Students in Recovery Colleges. Psychiatr Serv 2018 ; 69 (12) : 1222-1229.
PubMed
15) Crowther A, et al. The impact of Recovery Colleges on mental health staff, services and society. Epidemiol Psychiatr Sci 2019 ; 28 (5) : 481-488.
PubMed
16) Unger KV, et al. Rehabilitation through education : A university-based continuing education program for young adults with psychiatric disabilities on a university campus. Psychosocial Rehabilitation Journal 1987 ; 10 (3) : 35-49.
 
17) Ashcraft L, Anthony WA. A story of transformation : An agency fully embraces recovery. Behav Healthc Tomorrow 2005 ; 14 (2) : 12-13, 15-21.
 
18) Hutchinson DS. The Recovery Education Center : An integrated health promotion and wellness program. Psychiatr Rehabil J 2011 ; 34 (4) : 321-323.
PubMed
19) Anfossi A. The current state of Recovery Colleges in the UK : Final report. Nottingham : Implementing Recovery through Organizational Change ; 2017.
 
20) Whitley R, et al. Recovery colleges as a mental health innovation. World Psychiatry 2019 ; 18 (2) : 141-142
 
P.276 掲載の参考文献
1) 厚生省公衆衛生局精神衛生課. わが国の精神衛生 (1966年度版). https://www.ncnp.go.jp/nimh/pdf/fukushi1966.pdf (2019.9.4参照)
 
2) 国立研究開発法人国立精神・神経医療研究センター 精神保健研究所 精神医療政策研究部「精神保健福祉資料 [医療計画・障害福祉計画関連] 」https://www.ncnp.go.jp/nimh/seisaku/data/ (2019.9.4参照)
 
3) 長谷川敏彦. 日本医療の最後の暗部に光を求めて. 保健医療科学 2004 ; 53 (1) : 2-13. p8. 国立保健医療科学院. https://www.niph.go.jp/journal/data/53-1/200453010002.pdf (2019.9.4参照)
 
4) 今後の精神保健医療福祉のあり方等に関する検討会. 精神保健医療福祉の更なる改革に向けて. 2009年9月24日. https://www.mhlw.go.jp/shingi/2009/09/dl/s0924-2a.pdf (2019.9.4参照)
 
5) 日本精神科病院協会. 長期入院精神障害者の地域移行に向けた病院の構造改革の推進のための具体的方策のあり方に関する研究 報告書. 平成30年3月. https://www.mhlw.go.jp/content/12200000/000307943.pdf (2019.9.4参照)
 
6) 平成25～27年度 厚生労働科学研究費補助金 障害者対策総合研究事業. 精神障害者の重症度判定及び重症患者の治療体制等に関する研究. 研究結果の概要. ver.4.3. https://www.mhlw.go.jp/file/05-Shingikai-12201000-Shakaiengokyokushougaihokenfukushibu-Kikakuka/0000122522.pdf (2019.9.4参照)
 
7) 常に介護を必要とする障害者等のなかで, 特に介護の必要度が高い人に対して, 居宅介護, 重度訪問介護, 同行援護, 行動援護, 生活介護, 短期入所などのサービスを包括的に提供するもの. 重度障害者等包括支援. WAM NET. https://www.wam.go.jp/content/wamnet/pcpub/syogai/handbook/service/c078-p02-02-Shogai-14.html
 

5章 Topics - 変革に向けて

P.284 掲載の参考文献
1) 國分恭子, 松本和紀. 精神病におけるトラウマ-最近の研究の概観. トラウマティク・ストレス 2017 ; 15 (1) : 39-47.
 
2) Achim AM, et al. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull 2011 ; 37 : 811-821.
PubMed
3) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition. American Psychiatric Association ; 1980/高橋三郎ほか (訳). DSM-III 精神障害の分類と診断の手引. 医学書院 ; 1982.
 
4) 塩入俊樹. Fear circuitモデル. 飛鳥井望 (編), 心的外傷後ストレス障害 (PTSD). 最新医学社 ; 2011, pp60-70.
 
5) 鈴木章円, 井ノ口馨. 恐怖記憶の分子生物学. 飛鳥井望 (編), 心的外傷後ストレス障害 (PTSD). 最新医学社 ; 2011, pp80-90.
 
6) 友田明美. 脳科学から見たPTSD. 友田明美ほか (編), 子どものPTSD-診断と治療. 診断と治療社 ; 2014, pp94-101.
 
7) 大溪俊幸, 笠井清登. PTSDの画像研究. 飛鳥井望 (編), 心的外傷後ストレス障害 (PTSD). 最新医学社 ; 2011, pp71-79.
 
8) 小林佑衣ほか. 心的外傷後ストレス障害のトラウマ記憶に関わるメカニズム. BRAIN and NERVE 2018 ; 70 (7) : 813-820.
 
9) Steele W, Malchiodi CA. Trauma-Informed Practices With Children and Adolescents. New York : Routledge ; 2011.
 
10) Felitti V, et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE) Study. Am J Prev Med 1998 ; 14 : 245-258.
PubMed
11) 亀岡智美ほか. トラウマインフォームドケア-その歴史的展望. 精神経誌 2018 ; 120 : 173-185.
 
12) Hopper EK, et al. Shelter from the Storm : Trauma-Informed Care in Homelessness Services Settings. The Open Health Services and Policy Journal 2009 ; 2 : 131-151.
 
13) Harris M, Fallot RD. New Directions for Mental Health Services : Using Trauma Theory to Design Service Systems. San Francisco : Jossey-Bass ; 2001.
 
14) Substance Abuse and Mental Health Services Administration : SAMHSA's Concept of Trauma and Guidance for a Trauma-Informed Approach. HHS Publication No. (SMA) 14-4884. Rockville, MD : Substance Abuse and Mental Health Services Administration ; 2014/大阪教育大学学校危機メンタルサポートセンター・兵庫県こころのケアセンター (訳). SAMHSAのトラウマ概念とトラウマインフォームドアプローチのための手引き. 2018. 3. http://www.j-hits.org/child/pdf/5samhsa.pdf
 
15) Borckardt JJ, et al. Systematic investigation of initiatives to reduce seclusion and restraint in a state psychiatric hospital. Psychiatr Serv 2011 ; 62 (5) : 477-483.
 
16) Bryson SA, et al. What are effective strategies for implementing trauma-informed care in youth inpatient psychiatric and residential treatment settings? A realist systematic review. Int J Ment Health Syst 2017 ; 11 : 36.
PubMed
17) 日本精神科救急学会 (監修), 平田豊明, 杉山直也 (編). 精神科救急医療ガイドライン 2015年版. 日本精神科救急学会 ; 2016.
 
18) 杉山直也. 行動制限最小化に関する研究の報告. 厚生労働科学研究費補助金 (障害者対策総合研究事業), 精神科救急医療における適切な治療法とその有効性等の評価に関する研究 (H23-精神-一般-008) 平成24年度総括・分担報告書 (研究代表者 : 伊藤弘人). 2013. https://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201317047B
 
19) 坪井聡. 児童虐待の被害を測定する国際的調査票の日本語版の作成. 学術振興科学研究費助成事業研究成果報告書. 2014. https://kaken.nii.ac.jp/ja/file/KAKENHI-PROJECT-24790625/24790625seika.pdf
 
20) Kessler RC, et al. Childhood adversities and adult psychopathology in the WHO World Mental Health Surveys. Br J Psychiatry 2010 ; 197 : 378-385.
PubMed
21) Ho GWK, et al. Examining patterns of adversity in Chinese young adults using the Adverse Childhood Experiences-International Questionnaire (ACE-IQ). Child Abuse Negl 2019 ; 88 : 179-188.
PubMed
野坂祐子. トラウマインフォームドケア- "問題行動" を捉えなおす援助の視点. 日本評論社 ; 2019.
 
P.290 掲載の参考文献
1) The ADAPTE Collaboration. The ADAPTE Process : Resource Toolkit for Guideline Adaptation. Version 2.0. 2009. p95. http://www.g-i-n.net
 
2) Bhugra D, et al. The WPA-Lancet Psychiatry Commission on the Future of Psychiatry. Lancet Psychiatry 2017 ; 4 (10) : 775-818.
PubMed
3) Gaebel W, Moller HJ. European guidance : A project of the European Psychiatric Association. Eur Psychiatry 2012 ; 27 (2) : 65-67.
PubMed
4) Scottish Intercollegiate Guidelines Network. SIGN 50 : A guideline developer's handbook. Revised. SIGN ; 2019.
 
5) Gaebel W, et al. European Psychiatric Association (EPA) guidance on the quality of eMental health interventions in the treatment of psychotic disorders. Eur Arch Psychiatry Clin Neurosci 2016 ; 266 (2) : 125-137.
PubMed
6) Freeman D, et al. The effects of improving sleep on mental health (OASIS) : A randomised controlled trial with mediation analysis. Lancet Psychiatry 2017 ; 4 (10) : 749-758.
PubMed
7) Pot-Kolder RMCA, et al. Virtual-reality-based cognitive behavioural therapy versus waiting list control for paranoid ideation and social avoidance in patients with psychotic disorders : A single-blind randomised controlled trial. Lancet Psychiatry 2018 ; 5 (3) : 217-226.
PubMed
8) Craig TK, et al. AVATAR therapy for auditory verbal hallucinations in people with psychosis : A singleblind, randomised controlled trial. Lancet Psychiatry 2018 ; 5 (1) : 31-40.
 
9) Gaebel W, et al. EPA guidance on eMental health interventions in the treatment of posttraumatic stress disorder (PTSD). Eur Psychiatry 2017 ; 41 : 140-152.
PubMed
10) Heun R, Gaebel W. The relevance of EPA guidance papers in the framework of the European Psychiatric Association. Eur Psychiatry 2015 ; 30 (3) : 357-359.
PubMed
11) Mayer S, et al. European Psychiatric Association (EPA) guidance on post-graduate psychiatric training in Europe. Eur Psychiatry 2014 ; 29 (2) : 101-106.
PubMed
12) Brittlebank A, et al. Training in psychiatry throughout Europe. Eur Arch Psychiatry Clin Neurosci 2016 ; 266 (2) : 155-164.
PubMed
13) Schouler-Ocak M, et al. EPA guidance on cultural competence training. Eur Psychiatry 2015 ; 30 (3) : 431-440.
PubMed
14) Bhugra D, et al. EPA Guidance mental health care of migrants. Eur Psychiatry 2014 ; 29 (2) : 107-115.
PubMed
15) Martin-Carrasco M, et al. EPA guidance on mental health and economic crises in Europe. Eur Arch Psychiatry Clin Neurosci 2016 ; 266 (2) : 89-124.
PubMed
16) Fiorillo A, et al. Priorities for mental health research in Europe : A survey among national stakeholders' associations within the ROAMER project. World Psychiatry 2013 ; 12 (2) : 165-170.
PubMed
17) Lloyd K, White J. Democratizing clinical research. Nature 2011 ; 474 (7351) : 277-278.
PubMed
18) Boyce N, et al. Service user reviewers : Extending peer review in The Lancet Psychiatry. Lancet Psychiatry 2018 ; 5 (10) : 780-781.
PubMed
19) Iyer SN, et al. A minimum evaluation protocol and stepped-wedge cluster randomized trial of ACCESS Open Minds, a large Canadian youth mental health services transformation project. BMC Psychiatry 2019 ; 19 (1) : 273.
 
20) UK Public Involvement Standards Development Partnership. UK Standards for Public Involvement. NIHR ; 2019, p12. https://sites.google.com/nihr.ac.uk/pi-standards/home [cited 2020 Jan 19]
 
21) Ashcroft J, et al. Impact on the individual : What do patients and carers gain, lose and expect from being involved in research? J Ment Heal 2016 ; 25 (1) : 28-35.
 
22) Ennis L, Wykes T. Impact of patient involvement in mental health research : Longitudinal study. Br J Psychiatry 2013 ; 203 (5) : 381-386.
PubMed
23) Jennings H, et al. Best practice framework for Patient and Public Involvement (PPI) in collaborative data analysis of qualitative mental health research : Methodology development and refinement. BMC Psychiatry 2018 ; 18 (1) : 1-11.
PubMed
P.300 掲載の参考文献
1) 國井泰人ほか. わが国における精神疾患死後脳バンクの現状と問題点. 分子精神医学 2006 ; 6 (3) : 270-276.
Medical*Online
2) 丹羽真一ほか. 統合失調症死後脳研究. 臨床精神薬理 2009 ; 12 : 148-168.
 
3) 富田博秋. 第16章 ブレインバンク. 日本統合失調症学会 (監修), 福田正人ほか (編), 統合失調症. 医学書院 ; 2013, pp202-206.
 
4) Deep-Soboslay, et al. Psychiatric brain banking : Th ree perspectives on current trends and future directions. Biol Psychiatry 2011 ; 69 (2) : 104-112.
 
5) 國井泰人, 和田明. 生前登録システムに基づく精神疾患ブレインバンクの取り組み. 医学のあゆみ 2017 ; 261 (10) : 969-975.
 
6) Schmitt A, et al. How a neuropsychiatric brain bank should be run : A consensus paper of Brainnet Europe II. J Neural Transm 2007 ; 114 (5) : 527-537.
 
7) Sheedy D, et al. An Australian Brain Bank : A critical investment with a high return! Cell Tissue Bank 2008 ; 9 (3) : 205-216.
 
8) 柿田明美, 高橋均. ブレインリソースの現状-新潟大学脳研究所の取り組み. BRAIN and NERVE (神経研究の進歩) 2010 ; 62 (10) : 1019-1024.
 
9) 有馬邦正. 公的ブレイン・リソースの構築-リサーチ・リソース・ネットワークと生前同意に基づくパーキンソン病ブレインバンク. BRAIN and NERVE (神経研究の進歩) 2010 ; 62 (10) : 1025-1034.
 
10) 村山繁雄, 齊藤祐子. ブレインバンクの現状と展望. BRAIN and NERVE (神経研究の進歩) 2010 ; 62 (10) : 1013-1018.
 
11) 國井泰人ほか. 生前登録制度に基づく精神疾患ブレインバンクの実践-当事者と研究者が協働する研究体制とは. 精神経誌 2018 ; 120 : 269-276.
 
12) Kunii Y, et al. Elevated postmortem striatal t-DARPP expression in schizophrenia and associations with DRD2/ANKK1 polymorphism. Prog Neuropsychopharmacol Biol Psychiatry 2014 ; 53 : 123-128.
PubMed
13) Sakai M, et al. Assessment of copy number variations in the brain genome of schizophrenia patients. Mol Cytogenet 2015 ; 8 : 46.
PubMed
14) Hino M, et al. Decreased VEGFR2 expression and increased phosphorylated Akt1 in the prefrontal cortex of individuals with schizophrenia. J Psychiatr Res 2016 ; 82 : 100-108.
PubMed
15) Wada A, et al. Prominent increased calcineurin immunoreactivity in the superior temporal gyrus in schizophrenia : A postmortem study. Psychiatry Res 2016 ; 247 : 79-83.
PubMed
16) Matsumoto J, et al. Decreased 16:0/20:4-phosphatidylinositol level in the post-mortem prefrontal cortex of elderly patients with schizophrenia. Sci Rep 2017 ; 7 : 45050.
 
17) Seiriki K, et al. High-Speed and Scalable Whole-Brain Imaging in Rodents and Primates. Neuron 2017 ; 94 (6) : 1085-1100. e6.
 
18) Hirayama-Kurogi M, et al. Downregulation of GNA13-ERK network in prefrontal cortex of schizophrenia brain identified by combined focused and targeted quantitative proteomics. J Proteomics 2017 ; 158 : 31-42.
PubMed
19) Yukawa T, et al. Pathological alterations of chondroitin sulfate moiety in postmortem hippocampus of patients with schizophrenia. Psychiatry Res 2018 ; 270 : 940-946.
PubMed
20) 國井泰人. ブレインバンクと死後脳研究. 村井俊哉 (編), 統合失調症. 診断と治療のABC 別冊136号. 最新医学社 ; 2018, pp54-61.
 
P.310 掲載の参考文献
1) Kessler RC, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005 ; 62 (6) : 593-602.
PubMed
2) Gore FM, et al. Global burden of disease in young people aged 10-24 years : A systematic analysis. Lancet 2011 ; 377 (9783) : 2093-2102.
 
3) Whiteford HA, et al. Global burden of disease attributable to mental and substance use disorders : Findings from the Global Burden of Disease Study 2010. Lancet 2013 ; 382 (9904) : 1575-1586.
PubMed
4) Arai M, et al. Enhanced carbonyl stress in a subpopulation of schizophrenia. Arch Gen Psychiatry 2010 ; 67 (6) : 589-597.
 
5) Arai M, et al. Idiopathic carbonyl stress in a drug-naive case of at-risk mental state. Psychiatry Clin Neurosci 2011 ; 65 (6) : 606-607.
 
6) Arai M, et al. Carbonyl stress and schizophrenia. Psychiatry Clin Neurosci 2014 ; 68 (9) : 655-665.
PubMed
7) Miyashita M, et al. Replication of enhanced carbonyl stress in a subpopulation of schizophrenia. Psychiatry Clin Neurosci 2014 ; 68 (1) : 83-84.
 
8) Miyashita M, et al. Clinical features of schizophrenia with enhanced carbonyl stress. Schizophr Bull 2014 ; 40 (5) : 1040-1046.
PubMed
9) Itokawa M, et al. Pyridoxamine : A novel treatment for schizophrenia with enhanced carbonyl stress. Psychiatry Clin Neurosci 2018 ; 72 (1) : 35-44.
PubMed
10) Chaudhuri J, et al. The Role of Advanced Glycation End Products in Aging and Metabolic Diseases : Bridging Association and Causality. Cell Metab 2018 ; 28 (3) : 337-352.
PubMed
11) Bierhaus A, et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med 2012 ; 18 (6) : 926-933.
PubMed
12) Rabbani N, et al. Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics. Glycoconj J 2016 ; 33 (4) : 513-525.
PubMed
13) Kane J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988 ; 45 (9) : 789-796.
PubMed
14) Ueland PM, et al. Inflammation, vitamin B6 and related pathways. Mol Aspects Med 2017 ; 53 : 10-27.
PubMed
15) Mooney S, et al. Vitamin B6 : A long known compound of surprising complexity. Molecules 2009 ; 14 (1) : 329-351.
PubMed
16) Hellmann H, Mooney S. Vitamin B6 : A molecule for human health? Molecules 2010 ; 15 (1) : 442-459.
PubMed
17) 厚生労働省. 「日本人の食事摂取基準」 (2020年版). https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/eiyou/syokuji_kijyun.html
 
18) Voziyan PA, Hudson BG. Pyridoxamine as a multifunctional pharmaceutical : Targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci 2005 ; 62 (15) : 1671-1681.
PubMed
19) Chaudhuri J, et al. The Role of Advanced Glycation End Products in Aging and Metabolic Diseases : Bridging Association and Causality. Cell Metab 2018 ; 28 (3) : 337-352.
PubMed
20) Patton GC, et al. Adolescence and the next generation. Nature 2018 ; 554 (7693) : 458-466.
PubMed
21) Paus T, et al. Why do many psychiatric disorders emerge during adolescence? Nat Rev Neurosci 2008 ; 9 (12) : 947-957.
PubMed
22) Kondo S, et al. Premature deaths among individuals with severe mental illness after discharge from long-term hospitalisation in Japan : A naturalistic observation during a 24-year period. BJPsych Open 2017 ; 3 (4) : 193-195.
PubMed
精神疾患の克服と障害支援にむけた研究推進の提言. https://www.jspn.or.jp/uploads/uploads/files/activity/20180519.pdf
 
先制医療-予防医療の最前線. 診断と治療 2018 ; 106 (1).
Medical*Online
Strauss GP, Cohen AS. A Transdiagnostic Review of Negative Symptom Phenomenology and Etiology. Schizophr Bull 2017 ; 43 (4) : 712-719.
PubMed
Ott C, et al. Role of advanced glycation end products in cellular signaling. Redox Biol 2014 ; 2 : 411-429.
PubMed
Anwar A, et al. Advanced glycation end products, dityrosine and arginine transporter dysfunction in autism-a source of biomarkers for clinical diagnosis. Mol Autism 2018 ; 9 : 3.
PubMed
P.318 掲載の参考文献
1) Thornicroft G, Tansella M. Better Mental Health Care. Cambridge : Cambridge University Press ; 2009/岡崎祐士ほか (監訳), 精神保健サービス実践ガイド. 日本評論社 ; 2012.
 
2) 伊勢田堯, 西田淳志. 近年のイギリスにおける精神保健改革. 松原三郎ほか (編), <専門医のための精神科臨床リュミエール 22> 世界における精神科医療改革. 中山書店 ; 2010, pp24-40.
 
3) 厚生労働省. 精神障害者アウトリーチ推進事業の手引き. 2003. http://www.mhlw.go.jp/bunya/shougaihoken/service/dl/chiikiikou_03.pdf
 
4) 井上秀之. 統合失調症の早期支援と地域支援. 医学のあゆみ 2013 ; 246 : 295-299.
Medical*Online
5) 井上秀之. スポーツを通じた統合失調症のリカバリー. 日精協誌 2015 ; 34 (5) : 496-500.
 
6) 笠井清登ほか (編). 統合失調症UPDATE-脳・生活・人生の統合的理解にもとづく "価値医学" の最前線 (別冊・医学のあゆみ). 医歯薬出版 ; 2017.
 
7) Manary MP, et al. The patient experience and health outcomes. N Engl J Med 2013 ; 368 : 201-203.
PubMed
8) Jenkinson C. Patients' experiences and satisfaction with health care : Results of a questionnaire study of specific aspects of care. Qual Saf Health Care 2002 ; 11 (4) : 335-339.
PubMed

書評

最近チェックした商品履歴

Loading...